ALTASCIENCES

Meet Your Altascientists

ALTASCIENCES

Preclinical Experts

Clinical Experts

Bioanalytical Experts

Manufacturing and Analytical Experts

CRO Services Experts

Compliance and Quality Assurance Experts

Program and Project Managers

KEY PRECLINICAL RESEARCH EXPERTS

- Mike Broadhurst, Executive General Manager
- Ian Vanterpool, General Manager
- Linda Allais Hall, PhD, MSc, General Manager
- Francis Douville, Vice President, Technical Operations
- Dr. Norbert Makori, BVM, MSc, PhD, DABT, Vice President, Toxicology
- Dr. Wendell P. Davis, DVM, DACVP, Vice President, Pathology
- Dr. Jeffrey Burdick, DVM, DSP, Senior Director Veterinary Services and Technical Operations.
- Scott Boley, PhD, DABT, Senior Scientific Advisor
- Julie Forget, DESS Tox, DABT, Senior Director, Safety Assessment
- Alexander Walz, PhD, Senior Director, Safety Assessment
- Catherine (Catie) Selby, MS, Director, *In Vivo* Operations
- Isabel Tourigny, Director, *In Vivo* Operations
- Dr. Megan Haney, DVM, PhD, DACLAM, Director, Veterinary Services, Attending Veterinarian
- Dr. Simone Iwabe, DVM, PhD, DACVO, Senior Veterinary Ophthalmologist

MORE PRECLINICAL EXPERTS on next page

KEY PRECLINICAL RESEARCH EXPERTS

- Carmela Parente, Director, Preclinical Sponsor Liaison
- Dr. Emily Griffith, DVM, Associate Director, Surgical Services
- Lisa Biegel, Senior Scientific Director, Preclinical Services
- Andy Fecht, Director of Environmental Health and Safety
- Shayna Halverson, Director, Quality Assurance
- Dr. Eui Jae Sung, DVM, MS, PhD, DACVP, Veterinary Clinical Pathologist II
- Narine Lalayeva, MS, Director, Safety Assessment
- Jean-Christophe Queudot, Director, Safety Assessment
- Dr. Elaine Debien, DVM, DES, MSc, DACVP, Director, Pathology
- Anthony Andrade, BSc, Senior Manager, *In Vivo* Operations

PATHOLOGISTS/SCIENTISTS

- Dr. Keven Jackson, DVM, PhD, DACVP, Principal Pathologist
- Shunji Nakatsuji, PhD, DJSTP, DJCVP, Principal Pathologist
- Dr. Johanna Rigas, DVM, MS, DACVP, Veterinary Clinical Pathologist
- Yafei Chen, MS, Senior Research Fellow
- Dr. Tara Arndt, DVM, DACVP, Senior Director, Clinical Pathology

MORE PATHOLOGISTS/SCIENTISTS on next page

KEY PRECLINICAL RESEARCH EXPERTS

PATHOLOGISTS/SCIENTISTS

- Dr. Christina Ramirez, PhD, DVM, DACVP, Research Pathologist
- Dr. Divya Jose, BVSc, MSc, MVetSC, DACVP, Senior Research Pathologist
- Dr. Elinor Willis, VMD, PhD, DACVP, Research Pathologist
- Dr. Carolyn Gara-Boivin, DVM, MSc, DACVP, Veterinary Clinical Pathologist
- Dr. Camila Dores, DVM MSc, PhD, DACVP, Associate Director, Pathology
- Dr. Stephanie Fuetsch, MS, DVM, DACVP, Research Pathologist

STUDY DIRECTORS

- Kelsey Brooks, PhD, Scientist/Study Director, Safety Assessment
- Dr. Stefan Nechev, MD, DABT, Senior Toxicologist, Scientific Reviewer
- Dr. Li Zhan, MD, PhD, DABT, Research Scientist, Study Director
- Monserrath Camacho Ayala, MS, Scientist, Study Director
- Rosemary Cook, CVT, PhD, Scientist, Study Director
- Brian Klatt, Associate Scientific Director, Safety Pharmacology

MORE STUDY DIRECTORS on next page

KEY PRECLINICAL RESEARCH EXPERTS

STUDY DIRECTORS

- Breanna Colley, BA, Study Coordinator III
- Jay Pennell, MS, Principal Scientist, Study Director
- John MacMaster, Scientist/Study Director, Safety Assessment
- Tim Madsen, Associate Director, General Toxicology
- Kyle Klepner, Senior Scientist, Study Director
- Kaileigh McGinley, MS, RLAT, DABT, Principal Scientist, Study Director
- Miri Pannu, MS, Associate Scientific Director, Safety Pharmacology
- Jennifer Shenise, Associate Scientist, Study Director
- Vanessa Plummer, BS, Study Director
- Vishal Kothari, PhD, Scientist, Study Director
- Ashley Mahoney, MA, RLATG, Study Director
- Larry Karnes, BS, Scientist/Study Director
- Shanté Jackson, BA, Scientist, Study Director
- Ahmed Abdalla, PhD, MSc, Scientist, Study Director

MORE STUDY DIRECTORS on next page

KEY PRECLINICAL RESEARCH EXPERTS

STUDY DIRECTORS

- Sriram Devanathan, PhD, MBA, PMP, Scientist, Study Director
- Dusti Shay, PhD, Associate Scientist, Study Director
- Dr. Marianna Bacellar-Galdino, DVM, MSc, PhD, Veterinary Scientist, Ophthalmologist
- Maya Gilbert, BS, Study Director, Scientist
- Ashlee Harris, Study Director, Associate Scientist
- Hollie Bratcher, Study Director, Scientist
- Vanessa Thompson, PhD, Study Director, Research Scientist
- Yang Gao, PhD, Study Director, Associate Scientist
- Dinesh Thummuri, PhD, DABT, Study Director, Research Scientist
- Wendena Parkes, PhD, Study Director, Associate Scientist
- Nazar J. Hussein, PhD, Study Director, Research Scientist
- Justin Ulrich-Lewis, PhD, Study Director, Scientist
- Joel Skivington, MS, BS, Associate Scientist, Study Director
- Tyler Lilie, MBS, Associate Scientist, Study Director

MORE STUDY DIRECTORS on next page

Mike Broadhurst

Executive General Manager
Seattle, WA

Mike Broadhurst joined Altasciences in 2018. As Executive General Manager for Altasciences' preclinical facilities, Mike works closely with the executive management team to ensure the development and delivery of quality preclinical solutions that support both small and large molecules in all species, a scalable operational infrastructure, and streamlined processes.

With over 20 years of preclinical industry experience, Mike brings a breadth of knowledge to the Altasciences team. Prior to joining Altasciences, Mike was Senior Site Director at Charles River Laboratories, where he opened the company's first purpose-built toxicology facility in Canada, and later reopened a facility in Shrewsbury, MA.

Ian Vanterpool

General Manager
Columbia, MO

Ian joined Altasciences in 2020, with experience leading large, complex operational divisions supporting multinational research organizations in the life science sector. With a growth mindset, Ian has led effective and agile teams by identifying talent and supporting his team's leadership potential.

He has a proven track record of collaborating with different disciplines in a global organization, designing improvement strategies that enhance operational efficiency and profitability, promote regulatory compliance, and deliver real value to the customer. He has a passion for quality improvement and problem resolution and has gained considerable experience managing and navigating scientific and technical teams through periods of significant change.

Linda Allais Hall, PhD, MSc

General Manager
Scranton, PA

Linda Allais Hall joined Altasciences in 2025 as General Manager for the Scranton site. She began her career developing alternative methods at Sanofi before continuing her professional path in organizations in the UK (Inotiv), France, and the US (Charles River Laboratories).

She brings over 25 years of regulatory and scientific expertise in nonclinical safety assessment, and has held several key positions including study director, team leader, scientific program manager, director of toxicology, and senior director of toxicology and operations.

Linda holds a doctorate in Immunotoxicology and a Master of Science in Pharmacology and Toxicology. She has also authored several scientific publications and is a European registered toxicologist.

Francis Douville

Vice President, Technical Operations
Seattle, WA

Francis Douville joined the Altasciences team in 2018 as Vice President, Technical Operations. Francis has over 25 years of industry experience in both laboratory science and *in vivo* operations. Prior to joining Altasciences, he occupied several different positions at Charles River Laboratories, from entry-level technician to scientist, up to Director of *In Vivo* and Laboratory Sciences Operations.

Francis' career extends beyond his beginnings in Montréal, Canada; he opened a CRO in Shanghai, China, and joined a U.S. preclinical facility on the west coast. Prior to moving to Seattle, Francis was part of the team at Charles River Laboratories that reopened an east-coast facility in Shrewsbury, MA.

Dr. Norbert Makori, BVM, MSc, PhD, DABT

Vice President, Toxicology
Seattle, WA

Dr. Norbert Makori, BVM, MSc, PhD, DABT, joined Altasciences in 2021 as Vice President of Toxicology. He has over 20 years of industry experience as a toxicologist (general and reproductive toxicology), including roles as a study director, and in management. Prior to joining Altasciences, Norbert led the General Toxicology department at Charles River Laboratories' site in Ashland, OH, for five years. Prior to that, he held the position of Leader of Toxicology and Immunotoxicology at WIL Research Labs.

Norbert also led the reproductive toxicology team at SNBL (now known as Altasciences' preclinical site in Seattle), before it became part of the Altasciences family. Norbert is a diplomate of the American Board of Toxicology (DABT), and has a doctorate in Comparative Pathology.

Dr. Wendell Davis, DVM, DACVP

Vice President, Pathology
Seattle, WA

Dr. Wenddell Davis joined Altasciences in 2022. He is a nonclinical development professional with extensive experience in toxicologic pathology and a proven track record of building and leading high functioning pathology groups in both the biotechnology and CRO sectors. He is a proven leader with a passion for building pathology capabilities and mentoring pathologists, research, and laboratory scientists.

As a study pathologist and peer reviewer, he has experience evaluating small molecules, biologics, oligonucleotide, and an array of RNA therapeutics modalities across a range of preclinical species and routes of administration, in support of both early candidate selection and regulatory filings. Dr. Davis has co-authored over 25 publications, abstracts, and poster presentations. Prior to joining Altasciences, he held management roles in pathology and preclinical safety at Alnylam Pharmaceuticals, Charles River Laboratories, and Biogen Idec.

Wendell also maintains an active role in the industry as a member of the Society of Toxicologic Pathology and as a diplomate member of the American College of Veterinary Pathologists.

Dr. Jeffrey Burdick, DVM, DSP

Senior Director Veterinary Services
and Technical Operations
Scranton, PA

Dr. Jeffrey Burdick joined Altasciences in 2015. As site director and attending veterinarian, Jeffrey is fully involved in facility management at the Scranton preclinical site. He also manages the veterinary staff, animal care staff, necropsy team, and clinical pathology team.

Prior to joining Altasciences, he received his doctorate from the University of Pennsylvania, and completed an ACLAM residency program at GSK. Jeffrey has over 20 years of combined biomedical research experience in academic, pharmaceutical, and CRO settings.

Scott Boley, PhD, DABT

Senior Scientific Advisor
Columbia, MO

Dr. Boley has advised sponsors on their nonclinical needs for the last 15 years and had managed toxicology programs for over 19 years. He has extensive expertise in drug development as well as the regulatory expectations for a variety of test article types and indications. As Senior Scientific Advisor, Scott works with clients and business development to better design the nonclinical programs in support of each sponsor's safety programs.

Scott is a diplomate of the American Board of Toxicology, holds a Bachelor of Science in Biochemistry and a doctorate in Biochemistry/Environmental Toxicology from Michigan State University, MI.

Julie Forget, DESS Tox, DABT

Senior Director,
Safety Assessment
Seattle, WA

Julie Forget joined Altasciences in 2018 as Director, Safety Assessment, and became Senior Director in 2022. With over 19 years of experience in the preclinical industry, Julie brings scientific depth and expertise to the study director team, with a focus on delivering quality science to clients, from protocol development to report delivery.

Prior to joining Altasciences, Julie's expertise as a study director covered a large spectrum of study designs, from discovery to IND/NDA-enabling studies. Julie was also part of the team that developed the safety assessment capabilities at a Charles River Laboratories facility on the east coast, which contributed to her experience as manager.



Alexander Walz, PhD

Senior Director, Safety Assessment
Scranton, PA

Alexander Walz, PhD, joined Altasciences in 2008. From initial client contacts to protocol design, from study monitoring to data interpretation, Dr. Walz works closely with his clients through all aspects of GLP regulated, preclinical studies. He also works closely with the study directors to provide excellent scientific support and guidance, as well as supports the needs of our clients throughout the preclinical development process.

Prior to joining Altasciences, Alex's work experience includes design, development, and testing of novel antigen formulations using proteomics and genomics at a biotechnology company, as well as applied research on heat stress at the USDA. He earned his doctorate in Molecular Biology at the University of Dresden/Germany, in conjunction with the University of Minnesota, with highest honors.

Catherine (Catie) Selby, MS

Director, *In Vivo* Operations
Columbia, MO

Catie Selby has worked in biomedical research for 15 years in a variety of operational and research roles. Catie started her career as a research assistant in an academia role and moved to study director at Altasciences in 2012.

Since 2015, she has served as director of operations. In this capacity, she oversees scientific services, husbandry, quality control, training, clinical pathology and specimen management. Catie has a background in animal science, a Master of Science in swine reproduction, and experience in all aspects of study monitoring, study management, and staff development.

Isabel Tourigny

Director, *In Vivo* Operations
Seattle, WA

Isabel joined Altasciences in 2019. As Director of Operations, Isabel is responsible for husbandry, necropsy, histology, sample management, and scientific services for large and small animals.

She has over 22 years of preclinical industry experience, and has worked in different environments, departments, and countries within large CROs.

Dr. Megan Haney, DVM, PhD, DACLAM

Director, Veterinary Services,
Attending Veterinarian
Columbia, MO

Dr. Megan Haney joined Altasciences in 2019 and oversees the animal care program. In this capacity, she serves as Attending Veterinarian and manages the veterinary team.

She is involved in facility and operational management, in addition to oversight of surgical services, and assisting with model development. Prior to joining Altasciences, Megan received her veterinary doctorate from Kansas State University, KS, and completed a doctorate and ACLAM residency program at the University of Missouri, MO. She became a diplomate of the American College of Laboratory Animal Medicine after completing her board examination in 2020.

Dr. Simone Iwabe, DVM, PhD, DACVO

Senior Veterinary Ophthalmologist
Scranton, PA

Dr. Simone Iwabe is a board-certified veterinary ophthalmologist who joined Altasciences in 2020. She is responsible for conducting all the eye examinations, intravitreal and subretinal injections, ocular surgeries, and imaging procedures (fundus photography and OCT). Her expertise includes in gene therapy, retinal diseases, glaucoma, OCT, ERG, and ocular safety testing.

Simone received a Master of Science and a doctorate in Comparative Ophthalmology at the Autonomous National University of Mexico (UNAM), Mexico City. She is a diplomate of the American College of Veterinary Ophthalmologists (ACVO), and a member of the Association for Research in Vision and Ophthalmology (ARVO).

Carmela Parente

Director, Preclinical Sponsor Liaison

Carmela Parente joined Altasciences in 2022 with more than 27 years of industry experience in regulatory preclinical toxicology. She has provided expert input for the study design and interpretation of toxicological data, having conducted over 250 studies on pharmaceutical products, including acute, subacute and repeat dose, chronic, and reproductive toxicology. Prior to joining Altasciences, she held study director roles at Charles River Laboratories, subsequently moving into management positions.

As Director of Safety Assessment, she focused on scientific management and supporting staff, ensuring client satisfaction and delivery of high-quality and GLP-compliant reports. Additional roles included IACUC Chair, Process Improvement Lead, and Key Sponsor Portfolio Manager. In her current role, she provides leadership to, and oversight of, the preclinical program management team, as well as supporting sponsors through complete preclinical services support with subsequent clinical support.

Carmela is passionate about helping our clients get critical medicines to patients quickly by providing excellent client service with a personalized approach.

Dr. Emily Griffith, DVM

Associate Director, Surgical Services
Columbia, MO

Dr. Emily Griffith joined Altasciences in 2018 as a Staff Veterinarian, and is now Associate Director of Surgical Services. Emily oversees and manages the surgical staff, and assists with protocol and model development. Prior to joining our site, she received her doctoral degree from the University of Missouri's College of Veterinary Medicine, and worked as a clinical veterinarian in a private companion animal practice.

Lisa Biegel, PhD

Senior Scientific Director,
Preclinical Services
Columbia, MO

Lisa Biegel, PhD, joined Altasciences in 2022 and has more than 30 years of industry experience in regulatory toxicology at major organizations. She has provided expert input for the study design and interpretation of toxicological data, having conducted over 200 studies on pharmaceutical and agricultural products, including acute, subacute and repeat dose, chronic, and reproductive toxicology.

Lisa has authored or co-authored more than 25 peer-reviewed publications and presented at numerous conferences on toxicology, and other topics. Prior to joining Altasciences, she held research and study director roles at DuPont and Covance/Labcorp, subsequently moving into global management positions. In her most recent role as Vice President, Global Safety Assessment, Study Direction, Reporting and Data Management, she focused on scientific management and supporting staff development, ensuring timely communication, client satisfaction and delivery of high-quality and GLP-compliant reports and SEND datasets for regulatory submissions.

Lisa received a PhD in toxicology from Texas A&M University, TX. In her current role, she provides leadership and oversight to the study direction and reporting teams, as well as strategic scientific input for the site. She is passionate about helping our clients get critical medicines to patients as quickly as possible, while maintaining a focus on study quality, animal welfare, and employee development.



Andy Fecht

Director of Environmental Health and Safety
Columbia, MO

Andy Fecht joined Altasciences in 2022 as Director of Environmental Health and Safety. In this role, Andy oversees the site's compliance with local, state, and federal environmental, health and safety regulations.

Prior to joining Altasciences, Andy spent 20 years at Teva Pharmaceuticals in operations and safety management, where he implemented a best-in-class EHS program that was deployed across Teva's North American active pharmaceutical ingredient manufacturing facilities.

Shayna Halverson

Director, Quality Assurance
Seattle, WA

Shayna Halverson joined Altasciences in 2006. As the manager, quality assurance, at our preclinical facility, she works closely with the site's management team to maintain a pulse on quality and compliance with FDA GLP regulations, as well as sites across Altasciences to ensure a consistent approach. Shayna has been in the industry for over 13 years, and previously worked as a technician handling NHPs.

Dr. Eui Jae Sung, DVM, MS, PhD, DACVP

Veterinary Clinical Pathologist II
Seattle, WA

Dr. Eui Jae Sung joined Altasciences in 2025 and is an ACVP board-certified veterinary clinical pathologist with focused expertise in toxicologic clinical pathology for preclinical drug development. Before Altasciences, he served as a clinical pathologist at Charles River Laboratories, providing clinical pathology data interpretation and supporting sponsor communications across regulated nonclinical studies.

He earned his DVM and MS (Small Animal Internal Medicine) from Seoul National University, Korea, and completed a doctorate in Comparative Biomedical Sciences (Cell Biology focus) at North Carolina State University. His mechanistic research centered on innate immunity and cell signal transduction. He conducted molecular biology studies including protein-protein interactions, gene modification, and molecular target identification. Subsequently, he completed veterinary clinical pathology training at the National Institute of Environmental Health Sciences and National Toxicology Program.



Narine Lalayeva, MS

Director, Safety Assessment,
Seattle, WA

Narine joined Altasciences in 2005. She has over 19 years of experience conducting GLP and non-GLP studies with small and large molecules, with expertise in the conduct and direction of GLP preclinical toxicology studies, as well as the more specialized field of developmental and reproductive toxicology (DART).

She has targeted experience in general toxicology (single dose, multi dose, chronic, IND-enabling), DART (NHP and small animal), vaccine studies (small animals), intrathecal, and model development (diabetic NHP model). She has also been instrumental in the development of Altasciences' DART background dataset.

In her current role, Narine's focus has expanded to the development of a robust study director training program. In addition, Narine is in charge of the development of a new client satisfaction charter. This charter will enhance client experience with Altasciences by expanding on a foundation for building strong client relationships, fostering trust, and ensuring a positive experience throughout the project lifecycle.

Jean-Christophe Queudot

Director, Safety Assessment,
Seattle, WA

Jean-Christophe Queudot joined Altasciences in 2019 as Principal Scientist, Safety Pharmacology, and became Associate Director in 2023. With over 16 years of experience in the preclinical industry from toxicology to safety pharmacology, Jean-Christophe brings scientific guidance and expertise to the study director team and clients to refine the study design to reach the goal of the studies in compliance with the guidelines.

Prior to joining Altasciences, Jean-Christophe worked for different CROs in Europe and United States, and covered a large spectrum of study designs form early discovery to IND/NDA-enabling studies.

Dr. Elaine Debien, DVM, DES, MSc, DACVP

Clinical Pathology
Seattle, WA

Dr. Elaine Debien joined Altasciences in 2022, with over 10 years of toxicologic pathology experience in a GLP environment. She obtained her doctorate and a Master of Veterinary Sciences/Pathology at the Université de Montréal, where she also completed her residency program in veterinary anatomic pathology. She is a member of the Society of Toxicologic Pathology and a diplomate of the American College of Veterinary Pathologists.

Prior to joining Altasciences, Elaine was Senior Veterinary Pathologist at Charles River Laboratories, where she developed experience and interest for gene therapy, biotherapeutics, and intrathecal toxicity studies in NHPs, and carcinogenicity studies in transgenic mice.



Anthony Andrade, BSc

Senior Manager, *In Vivo* Operations
Sacramento, CA

Anthony Andrade, BS, joined Altasciences in 2025 as Senior Manager of *In Vivo* Operations. In this role, he oversees the daily performance of preclinical studies, manages technical staff, coordinates resources, and ensures operational efficiency across all *in vivo* functions. Prior to joining Altasciences, Anthony served as Project Manager,Research at JOINN Laboratories (Biomere), where he led *in vivo* teams conducting discovery studies in nonhuman primates and rodents.

Anthony was responsible for supervising study execution, managing resources, and preparing study documentation, including protocols, amendments, and reports. Anthony earned a Bachelor of Science in Animal Science, with a minor in Education from the University of California, Davis.

Dr. Keven Jackson, DVM, PhD, DACVP

Principal Pathologist
Seattle, WA

Dr. Kevin Jackson joined Altasciences in 2002, and offers 36 years of pathology experience and 18 years of experience in toxicological pathology. He has a Doctor of Veterinary Medicine from Louisiana State University, anatomic pathology residency training, and a doctorate in Veterinary Microbiology from the Washington State University.

Shunji Nakatsuji, PhD, DJSTP, DJCVP

Principal Pathologist
Seattle, WA

Shunji Nakatsuji, PhD, DJSTP, DJCVP, joined Altasciences in 2015 as a pathologist with 30 years' experience in the pharmaceutical industry in Japan, including 10 years at Astellas. Shunji received a Bachelor of Science and a Master of Science in Agricultural Sciences from Kobe University, and a doctorate in Veterinary Pathology from Osaka Prefecture University.

He is a diplomate of both the Japanese College of Veterinary Pathologists (DJCVP), and the Japanese Society of Toxicologic Pathologists (DJSTP). Shunji has been an active member of the INHAND working group of the Society of Toxicologic Pathology since 2010.

Dr. Johanna Rigas, DVM, MS, DACVP

Veterinary Clinical Pathologist
Seattle, WA

Dr. Johanna Rigas joined Altasciences in 2021 and is a board-certified veterinary clinical pathologist with extensive experience in clinical pathology laboratory development and management, clinical diagnostic pathology, and teaching veterinary medical programs.

Johanna completed a residency in veterinary clinical pathology, after earning a Doctor of Veterinary Medicine from Oregon State University. She also holds a Master of Biology from Portland State University, with thesis work performed in biomedical research at Oregon Health & Science University.



Yafei Chen, MS

Senior Research Fellow
Columbia, MO

Yafei Chen joined Altasciences in 2021. Prior to joining, he held study director and study monitor roles at CROs and pharmaceutical companies, including AstraZeneca and Janssen. Yafei has 18 years of experience in general toxicology, safety pharmacology, and investigative biomarkers.

Yafei is experienced in providing expert input into the study design and interpretation of toxicological data, ensuring timely communication and delivery of high-quality and GLP compliant reports for regulatory submissions. He is proficient in providing expert input into the study design and interpretation of toxicological data.

A graduate from Peking Union Medical College, with a Master of Science in Clinical Biochemistry, Yafei's research work includes renal, neuro, and immunotoxicity, with a current passion for developing and promoting gene therapy models in miniature swine.

Dr. Tara Arndt, DVM, DACVP

Senior Director, Clinical Pathology
Seattle, WA

Dr. Tara Arndt joined Altasciences in 2023. She is a dual board-certified ACVP veterinary anatomic and clinical pathologist with extensive experience in regulatory toxicological pathology, including discovery and preclinical development. Tara completed a clinical pathology residency program at the University of California, Davis, and became a diplomate of ACVP in 2007 (clinical pathology). She obtained dual ACVP board certification in 2013 (anatomic pathology) after briefly training at the University of Guelph, Ontario Veterinary College in Canada.

Tara served as Senior Toxicologic Clinical Pathologist at Labcorp (previously Covance) for almost a decade before joining Altasciences. She is an active member of several impactful ASVCP, ACVP, STP, and ESTP committees and working groups, has chaired and presented at international symposia, and has authored or co-authored several manuscripts and book chapters on diagnostic and toxicologic clinical pathology.

When not working, you will likely find her somewhere in the great outdoors, focusing on wildlife and landscape photography, ecology, and conservation.

Dr. Christina Ramirez, DVM, PhD, DACVP

Research Pathologist
Seattle, WA

Dr. Christina Ramirez joined Altasciences in 2024, bringing with her a broad spectrum of experience including experimental pathology, diagnostic pathology, genetic disease research, and diagnostic genetic testing.

A board-certified veterinary anatomic pathologist, she has a doctorate in Molecular and Cellular Biology from the University of Washington, as well as a doctorate in Veterinary Medicine from Washington State University.

Christina completed a residency in Veterinary Anatomic Pathology at the University of Missouri, and became a diplomate of the American College of Veterinary Pathology in 2014.

Dr. Divya Jose, BVSc, MSc, MVetSC, DACVP

Senior Research Pathologist
Seattle, WA

Dr. Divya Jose joined Altasciences in 2024, bringing four years of experience in regulatory toxicologic pathology. She obtained her veterinary degree from Kerala Agricultural University, India, and has a Master of Veterinary Science in Animal nutrition, and Veterinary Anatomic pathology from University of Saskatchewan, Canada. She completed residency in Veterinary Anatomic Pathology at Western College of Veterinary medicine, Canada, and became a Diplomate of the American College of Veterinary Pathologists in 2021. She is an active member of ACVP and STP.

Prior to joining Altasciences, Divya served as a Veterinary Anatomic Pathologist at Charles River Laboratories, where she has developed an interest in reproductive toxicology.



Dr. Elinor Willis, VMD, PhD DACVP

Research Pathologist
Scranton, PA

Dr. Elinor Willis joined Altasciences in 2024. She received a Doctor of Veterinary Medicine and a Doctorate in virology and immunology from the University of Pennsylvania, focusing on antiviral immunity and vaccines. She completed a residency in veterinary anatomic pathology at UPenn and became a Diplomate of the American College of Veterinary Pathologists in 2023.

Elinor recently completed a postdoctoral fellowship with the University of Pennsylvania's Comparative Pathology Core. Her experience includes immunology, infectious diseases, vaccines, cellular therapies, and humanized mouse models.

Dr. Carolyn Gara-Boivin, DVM, MSc, DACVP

Veterinary Clinical Pathologist
Columbia, MO

Dr. Carolyn Gara-Boivin joined Altasciences in 2024. She earned her Doctor of Veterinary Medicine and Master of Science in Veterinary Sciences/Clinical Pathology from the University of Montréal, where she also completed a residency in Veterinary Clinical Pathology. In 2012, Carolyn became a Diplomate of the American College of Veterinary Pathologists (Clinical Pathology).

With 12 years of experience as an Associate Professor of Clinical Pathology at the University of Montréal, Carolyn has made valuable contributions to the field through numerous publications and co-authorships, as well as presentations at international conferences. Her research is focused on coagulation and anticoagulants, urinalysis, and establishing hematological reference values in exotic species.

Dr. Camila Dores, DVM, MSc, PhD, DACVP

Associate Director, Pathology,
Columbia, MO

Dr. Camila Dores joined Altasciences in 2023. She is a DVM, MSc, Ph.D. Diplomate ACVP in Anatomic Pathology, with extensive experience in toxicology and comparative pathology. Camila worked in academia as an associate professor and director of biopsy and necropsy services and in research and toxicology pathology laboratories as a comparative pathologist before joining Altasciences' team.

Camila earned her DVM from São Paulo State University in 2005. She also obtained a Master's degree from São Paulo State University and The Baker Institute at Cornell University, followed by a PhD in Comparative Biology and Experimental Medicine from the University of Calgary, AB. After her graduate studies, she joined the Anatomic Pathology Residency program at Oregon State University, achieving ACVP board certification in 2019.

Camila serves on multiple committees at the Society of Toxicology Pathology and has published numerous manuscripts. At Altasciences, she is an Associate Director of Pathology, where she plays a key role in enhancing the company's scientific capabilities and areas of expertise. She has a particular interest in the pathology of the central nervous system, reproductive toxicology, and the integration of in vitro systems in toxicological pathology.

Dr. Stephanie Fuetsch, MS, DVM, DACVP

Research Pathologist
Seattle, WA

Dr. Stephanie Fuetsch joined Altasciences in 2025 after completing a residency in Veterinary Comparative Pathology at North Carolina State University and the University of North Carolina. She obtained her veterinary degree from the University of California, Davis, and her Bachelor and Master of Science degrees in Biology at the University of Nevada, Reno, NV. She became a Diplomate of the American College of Veterinary Pathologists in 2024.

Stephanie has performed benchtop science and collaborative research at multiple institutions and has a background in environmental health and safety. She has worked with various species and animal models that include mice, canines, rats, zebrafish, and swine.

Kelsey Brooks, PhD

Scientist, Study Director
Seattle, WA

Kelsey Brooks, PhD, joined Altasciences in 2019, with a focus on chromosome segregation abnormalities during early embryo development. Prior to joining Altasciences, Kelsey completed her postdoctoral fellowship at the Oregon National Primate Research Center, outside of Portland, OR.

Dr. Stefan Nechev, MD, DABT

Senior Toxicologist,
Scientific Reviewer,
Seattle, WA

Dr. Stefan Nechev joined Altasciences in 2005. With 23 years of preclinical CRO experience (immunotoxicology, general toxicology, and clinical pathology), Stefan is a board-certified toxicologist with a Doctor of Medicine background.

Stefan's expertise includes general medicine, biochemistry, clinical pathology, immunotoxicology, and animal research. He has directed or assisted in the data interpretation of preclinical rodent, and non-rodent safety assessment studies.

Dr. Li Zhan, MD, PhD, DABT

Research Scientist, Study Director,
Seattle, WA

Dr. Li Zhan joined Altasciences in 2015. With 10 years of experience as a board-certified toxicologist, Zhan has experience in toxicology and related fields (cardiovascular and genetic toxicology).

With four years of experience working as a study director on GLP preclinical safety studies at CRO West China-Frontier Pharma Tech Co., Ltd., three years of genetic toxicology, and six years of cardiovascular toxicology experience in the academia arena, Zhan served as a postdoctoral fellow at the Indiana University School of Medicine, and at the School of Medicine at the University of Louisville School of Medicine.

Monserrath Camacho Ayala, MS

Scientist, Study Director
Scranton, PA

Monserrath joined Altasciences in 2021. As Study Director, she works closely with clients, consultants, and internal team members to develop and execute preclinical studies involving small and large animals. Having graduated from the University of Scranton with a Bachelor of Science in Biology and a Master of Science in Biochemistry, her thesis work focused on protein purification and neuronal redox homeostasis in rodent models.

Prior to joining Altasciences, Monserrath worked at a clinical infectious disease lab where she participated in the validation of novel molecular testing procedures and related computer systems, quality assurance, and team management.

Rosemary Cook, CVT, PhD

Scientist, Study Director
Scranton, PA

Rosemary Cook, PhD, joined Altasciences' toxicology department as a study director, directing both non-GLP and GLP studies with an expertise in running studies in both large and small animals. Rosemary is also a licensed veterinary technician and has experience with laboratory animals, exotic animals, large animals, and companion animal medicine.

Prior to becoming a study director, Rosemary chaired a veterinary technology program for over a decade. Her graduate work focused on DNA vaccine development targeting the adult stage of Schistosoma mansoni. This work implemented a novel surgical technique that allowed for implantation of adult worms into the mesenteric circulation of mice, thus bypassing the larval stages of the parasite.

Brian Klatt

Associate Scientific Director,
Safety Pharmacology
Scranton, PA

Brian Klatt joined Altasciences in 1987 and has a Bachelor of Science in Biology. He began as a pharmacology research technician and worked his way up to Associate Scientific Director, Safety Pharmacology. He also serves as a study director for CNS, respiratory, and cardiovascular studies, for which he is responsible for all aspects, from protocol development through to final report preparation.

In his 34 years of experience, he has conducted many of the various discovery pharmacology studies, such as anti-inflammatory, analgesia models, cardiovascular, and more.

Breanna Colley, BA

Study Coordinator III
Columbia, MO

Breanna Colley joined Altasciences in 2019 as a Study Coordinator, bringing over 10 years of experience in the toxicology field. She graduated with a Bachelor of Arts in Biology from Columbia College, MO, in 2017. She assumed her current role as Study Coordinator III in 2023.

As Study Coordinator III, Breanna holds a dual role as Study Coordinator and Study Director on non-GLP pharmacokinetic studies. With her knowledge and time at Altasciences, she has become a certified trainer, providing mentoring and training to many other study coordinators over the years.

Breanna has experience with a wide variety of non-GLP/GLP studies for both rodent and non-rodent animal models. She relishes learning about the indication of new compounds, discovering each client's goals, and how Altasciences can make those goals a reality. Each day, she is motivated by seeing how the work at Altasciences makes an impact on human and animal medicine.

Jay Pennell, MS

Principal Scientist, Study Director
Scranton, PA

Jay joined Altasciences as a study director in 2006 and has since directed hundreds of toxicology studies. Jay has worked with a wide variety of small and large animal species, and has experience with ocular, oral, dermal, and parenteral dose routes. At Altasciences, Jay has been primarily involved in ophthalmic products, including formulations applied topically to the surface of the eye and eyelids—and liquid, gel and solid formulations administered intravitreally.

Prior to joining Altasciences, he worked with a CRO in upstate New York, where he conducted acute toxicology. Jay has over 20 years of professional experience in nonclinical safety evaluation. As a Master's student, he conducted toxicologic experiments designed to better understand the mechanisms by which heavy metals inflict injury on the renal proximal tubule (RPT) and how those injuries, in turn, impact the transport of molecules across the RPT.

John MacMaster

Scientist, Study Director,
Seattle, WA

John MacMaster joined Altasciences in 2021, bringing 20 years of experience in conducting large and small molecule drug discovery studies at major biotech and pharmaceutical companies. His area of expertise is conducting small animal efficacy studies for oncology and autoimmune disease. John earned a Bachelor of Science at the University of California, Davis where he developed an interest in wine, and has spent some time as an analytical chemist and educator in the wine industry.

John is excited to be involved in the next step of the drug development process, helping sponsors advance their programs into the clinic, safely and seamlessly.

Tim Madsen

Associate Director, General Toxicology
Columbia, MO

Tim Madsen joined Altasciences in 2003, and has approximately 35 years of industry experience in regulatory toxicology. Tim has served as a GLP Study Director, conducting a significant number of animal health studies (safety, dental, and diet), along with surgical device, diabetic testing, wound-healing, and general toxicology studies. In his current role, he provides leadership and oversight to the study direction team. In addition, Tim serves as the facility's unofficial historian and storyteller.

Tim graduated with a Bachelor of Arts in Biology from Central Methodist College in Fayette, MO. Prior to joining Altasciences, he spent more than 14 years in metabolism chemistry and aquatic toxicology divisions at ABC Laboratories in Columbia, MO.

When not working, you will likely find him performing a prairie restoration project, bird watching, and/or hiking in a national park somewhere around the world.



Kyle Klepner

Senior Study Director
Columbia, MO

Kyle Klepner joined Altasciences more than 13 years ago, and has held a variety of operational and project management roles. Kyle is experienced in all aspects of study monitoring, test article preparation, sample handling, data collection, and management. He is driven by a passion for animal welfare, health, and science.

A graduate of the University of Missouri, MO, Kyle has participated in a wide variety of animal model development and non-GLP and GLP toxicology studies to meet IND-enabling requirements. In addition, he has an extensive background with infusions in large animal models using various infusion pumps, including stationary syringe pumps and ambulatory peristaltic pumps, as well as managing and overseeing efficacy and pharmacokinetic/pharmacodynamic studies in the diabetic minipig animal model.



Kaileigh McGinley, MS, RLAT, DABT

Principal Scientist,
Study Director
Columbia, MO

Kaileigh McGinley joined Altasciences in 2012 as an animal technician after graduating with a Bachelor of Science in animal science from the University of Missouri. She moved into the research department in 2013, primarily working with Type I diabetic pig models in pharmacodynamic/pharmacokinetic studies.

While working as a study director, Kaileigh achieved a Master of Science in Integrative Pharmacology from Michigan State University. She currently conducts the CNS safety pharmacology studies for Altasciences. Kaileigh has experience with a wide variety of non-GLP/GLP toxicology, efficacy, and IND-enabling studies for both rodent and non-rodent animal models, and has worked with all aspects of study monitoring, test article management, and data collection and management.

Kaileigh enjoys learning about the indication and mechanism of action for each new compound she works with, and teaching others at Altasciences how their daily work makes an impact on human and animal medicine.

Miri Pannu, MS

Associate Scientific Director
Columbia, MO

Miri joined Altasciences in 2017. As a research and development scientist, Miri works closely with the scientific committee to ensure the development of preclinical solutions that support new animal models and *in vivo* and *in vitro* assays.

As a study director, Miri has been running GLP studies for over five years, with a primary focus on cardiovascular and cardiopulmonary safety pharmacology studies in telemetered canines and miniature swine. Prior to joining Altasciences, Miri completed a Bachelor of Science in Biology at St. Louis University, MO, and earned a Master of Science in Biomedical Sciences, with thesis work performed in medical microbiology and immunology at A.T. Still University–Kirksville College of Osteopathic Medicine.

Miri's personal inspiration and motivation for pursing the research field stems from her enthusiasm for working with clients, and seeing how her efforts contribute to developing and achieving their preclinical goals.

Jennifer Shenise

Associate Scientist,
Study Director
Scranton, PA

Jennifer Shenise joined Altasciences in 2001 and holds an associate's degree in veterinary animal science. She began as a research associate in toxicology, transferred to safety pharmacology in 2005, before becoming a study director in 2021. Jennifer is responsible for planning, coordinating, and supervising interdepartmental activities during all phases of telemetered cardiovascular studies. She also plays an integral role in the surgical preparation of telemetry colony animals.

Vanessa Plummer, BS

Study Director
Columbia, MO

Vanessa Plummer joined Altasciences in 2023 as a study director, having previously worked as a quality engineer for 3M in Columbia, MO. Vanessa graduated from the University of Missouri-Columbia with a Bachelor of Science in Animal Science, minoring in Biology and Chemistry. While studying, she also worked in the university's Animal Science Research Center.

Vanessa specializes in agriculture animal science, and has accumulated more than 25 years' experience in various quality and regulatory affairs positions across the drug development field; both in GLP and GMP environments. Vanessa is proud to work for Altasciences and takes great satisfaction from her ability to contribute towards improving lives. She is always looking to the future for more rewarding and meaningful experiences.

Vishal Kothari, PhD

Scientist, Study Director
Seattle, WA

Vishal Kothari, PhD, joined Altasciences in 2022 as a study director. He has broad and extensive experience in designing and running various preclinical studies with small and large molecules. Prior to joining Altasciences, Vishal completed his postdoctoral fellowship at the University of Washington, School of Medicine.

In addition, he has 5 years of experience working as a scientist on cardiometabolic diseases, relevant preclinical studies at Eurofins Advinus, India.

Ashley Mahoney, MA, RLATG

Study Director
Sacramento, CA

Ashley joined Altasciences in 2021, and became study director in 2022. As Study Director, she performs non-GLP discovery studies at the Sacramento site. Ashley is a Registered Laboratory Animal Technologist, and possesses a Master of Science in Psychology from California State University, Sacramento, CA, where her thesis work focused on elucidating the function of the perirhinal cortex in learning and memory processes.

Prior to joining Altasciences, Ashley was a research associate at the University of California, Davis, where she worked with small and large animal models of spinal cord injury in a neuroengineering lab.

Larry Karnes, BS

Scientist, Study Director
Columbia, MO

Larry Karnes joined Altasciences in 2013 as an animal technician after graduating with a Bachelor of Science in Biology from the Central Methodist University, MO. He subsequently moved into the research department in 2014 and worked in various study types, including pharmacodynamic, pharmacokinetic, and dermal toxicology.

While working as a study director, Larry continues to expand his experience in a wide variety of non-GLP and GLP toxicology, efficacy, biologics, and IND-enabling studies, for both rodent and non-rodent animal models. Additionally, he has worked in all aspects of study monitoring, test article management, and data collection and management.

Larry is proud to be a part of Altasciences, as the work he performs improves lives. He enjoys learning about new compounds, and working with sponsors to help them meet their timelines and achieve their goals.

Shanté Jackson, BS

Scientist, Study Director
Columbia, MO

Shanté Jackson joined as a study coordinator in August 2021, and quickly transitioned to her current role as study director in May 2022. As Study Director, Shanté has experience with running studies in accordance GLP standards, standard operating procedures (SOPs), and regulatory agency expectations, with a primary focus on nonclinical research in rodents, canines, and miniature swine.

Prior to joining Altasciences, Shanté completed a Bachelor of Science in Biochemistry at Kenyon College, OH, and was involved in graduate study research related to pharmaceutical sciences, pharmacology and toxicology. She began working in the industry as study director for drug metabolism, drug inhibition, and drug transport at an *in vitro* research CRO.

Shanté's personal motivation for pursing the research field stems from her passion for working with clients, which ultimately allows her to contribute to the development and achievement of various nonclinical goals as a crucial steppingstone for potential, future life-changing compounds.

Ahmed Abdalla, PhD, MSc

Scientist, Study Director,
Columbia, MO

Ahmed Abdalla, PhD, joined Altasciences in 2022 and has been in the field of research since 2008, having earned a Master of Science in Animal Health from North Carolina Agricultural and Technical State University in 2013, and a Doctorate in Toxicology from Iowa State University in 2022.

Throughout his career, he has held various positions in both academia and the pharmaceutical industry, including roles as a Laboratory Technologist, Research Assistant, and Veterinary Diagnostic Services Scientist.

Ahmed is driven by a passion for preclinical research, and a desire to make a tangible difference in the lives of patients by discovering new treatments and potential cures for diseases.

Sriram Devanathan, PhD, MBA, PMP

Scientist, Study Director,
Columbia, MO

Sriram Devanathan joined the Altasciences team in 2024, bringing with him over 13 years of postdoctoral experience. Dr. Devanathan collaborates with a diverse array of global stakeholders and clients, the business development team, and regulatory consultants, to lead the planning, organization, and execution of research in strict adherence to regulatory standards, protocols, and guidelines such as EMA, FDA, GLP, and GCP.

Sriram received a Doctorate in Chemistry and Biochemistry from Miami University of Ohio, and is certified in Drug Development (UCSD), Six Sigma (KPMG), and as a Project Management Professional (PMI). His past research and work have spanned the development of novel biomarkers for metabolic diseases, targeted drug therapies for oncology, and small molecule therapeutics for neurological disorders.

Sriram's passion for translating scientific advancements into improved treatments at the bench side drives his work, and he has been recognized by regional business councils and business journals for his scientific contributions.

Dusti Shay, PhD

Associate Scientist, Study Director,
Columbia, MO

Dusti Shay, PhD, joined Altasciences in 2024 after completing a doctorate in Exercise Physiology at the University of Missouri, Columbia. As an academic researcher, Dusti specialized in preclinical addiction neuroscience, administering estrogen directly into the brain of rodent models using stereotaxic methods and assessing behavioral outcomes.

As a Study Director, Dusti works closely with clients to successfully perform GLP and non-GLP safety assessment studies across multiple preclinical models and dose routes. Working at Altasciences allows her to expand her current knowledgebase and continue to grow as a scientist.

Dr. Marianna Bacellar-Galdino, DVM, MSc, PhD

Scientist, Study Director, Scranton, PA

Dr. Marianna Bacellar-Galdino, DVM, MSc, PhD, joined Altasciences as a Study Director in 2024. She is a veterinary ophthalmologist with expertise in development and refinement of animals for ophthalmic indications, as well as gene therapy, retinal diseases, glaucoma, AMD, OCT, ERG and ocular efficacy testing.

Marianna received a Master of Science in veterinary ophthalmology at the Federal University of Parana (UFPR-Brazil), and a doctorate in Comparative Medicine and Integrative Biology with focus in comparative ophthalmology at Michigan State University (MSU). She also serves as an affiliate faculty member in the Department of Ophthalmology at Loyola University Chicago, IL, and is a member of the Association for Research in Vision and Ophthalmology (ARVO).

Maya Gilbert, BS

Study Director, Scientist

Maya Gilbert joined Altasciences in 2024 as a Study Director, bringing over 6 years of CRO industry experience conducting preclinical GLP and non-GLP studies. Maya has expertise in small and large molecule pharmaceutical, crop protection, and chemical studies with FDA, EPA, and OECD compliance. She has experience in general toxicology and developmental and reproductive toxicology studies.

Maya holds a Bachelor of Science in Ecology and Evolutionary Biology from the University of Michigan, where she volunteered curating the mammalian collection at the Museum of Zoology, and researched the hunting behavior of and tracked coyote-wolf hybrids in northern Michigan.

Ashlee Harris, BS

Study Director, Associate Scientist

Ashlee joined Altasciences in 2022 as Research Associate, transitioning to Study Supervisor in 2023, and into her current role as Study Director in 2024. She works closely with the operational team to coordinate preclinical studies in nonhuman primates.

Prior to joining Altasciences, Ashlee received her Bachelor of Science in Animal Science, specializing in animal behavior from the University of California, Davis. During her undergraduate, she interned at the California National Primate Research Center assisting in sample and observational data collection with Titi monkeys.

Hollie Bratcher

Study Director, Scientist

Hollie Bratcher has been a part of the Altasciences team since 2019, with 19 years of overall experience in the preclinical industry. She has worked in the preclinical industry since 2006, beginning her career with a focus on large animal toxicology as a research technician at MPI Research in Mattawan, Michigan.

Hollie later gained further experience in study planning and resource management as an *in vivo* operations manager. In 2022, she brought her extensive *in vivo* experience to the Altasciences study director team in which she worked on studies such as target animal health and safety, surgical and medical device models and small and large molecule IND-enabling packages, both in rodent and non-rodent species.

Hollie earned her Bachelor of Science Degree in Biology from the University of Southern Indiana in 2006.

Vanessa Thompson, PhD

Study Director, Research Scientist

Vanessa Thompson joined Altasciences in 2024, bringing expertise in conducting pharmacokinetic, efficacy, and toxicology studies in animals. She graduated from Florida International University with a doctorate in Chemistry, and has since served in various roles in research, laboratory management, compliance, and toxicology. She previously served as GLP Manager and study director on a wide variety of oncology-related treatments.

When not in the lab, Vanessa enjoys reading, painting, playing video games, and watching her beloved Philadelphia Eagles play.

Yang Gao, PhD

Study Director, Associate Scientist

Yang Gao joined Altasciences in 2025 as Study Director, bringing over a decade of experience in oncology drug discovery and preclinical development, with a strong focus on small molecule inhibitors and targeted protein degradation. Yang leads GLP-compliant nonclinical studies with full accountability for technical conduct, regulatory alignment, and client engagement. Her role includes protocol design, cross-functional coordination, and milestone tracking, ensuring scientific rigor and operational excellence.

Yang previously held leadership and senior scientist roles at Talus Bioscience, Exo Therapeutics, and Dana-Farber Cancer Institute. She has driven the development of first-in-class small molecule inhibitors, pioneered novel assay platforms, and contributed to multiple IND-enabling programs.



Dinesh Thummuri, PhD, DABT

Study Director, Research Scientist

Dinesh Thummuri is a board-certified toxicologist with over 6 years of experience in preclinical drug development and toxicology, who joined Altasciences in 2025. He has successfully led cross-functional teams and delivered critical safety assessments supporting both early- and late-stage drug development.

Prior to joining Altasciences, he served as Project Toxicologist at Takeda, where he contributed to several immuno-oncology programs and led the design and implementation of early toxicology strategies. Notably, he played a key role in the preclinical development of DT2216, a first-in-class selective BCL-XL degrader currently in Phase I clinical trials, and in the advancement of dual BCL-XL/BCL-2 degraders.

Dinesh's research has been published in leading scientific journals, including Nature Medicine, Nature Communications, Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Molecular Cancer Therapeutics, and Proceedings of the National Academy of Sciences (PNAS), among others. He is also a co-inventor on three U.S. patents related to BCL-XL degraders and dual BCL-XL/BCL-2 degraders.

Wendena Parkes, PhD, BSc

Study Director, Associate Scientist

Wendena Parkes joined Altasciences in 2024 as a study director, bringing with her a strong scientific background and a passion for advancing preclinical research. In her role, she is responsible for the design, oversight, and execution of both non-GLP and GLP-compliant studies, contributing to the development of high-quality, IND-enabling data packages for regulatory submission.

Wendena holds a Bachelor of Science in Biology with a minor in Chemistry, and earned her doctorate in Toxicology, where her research focused on ovarian reproduction and liver regeneration. She is committed to scientific excellence and ensuring the integrity and reliability of preclinical data in support of drug development.

Nazar J. Hussein, PhD

Study Director, Research Scientist

Nazar Hussein joined Altasciences in 2025 as Study Director, Research Scientist. He has led numerous GLP and non-GLP toxicology studies supporting IND applications, across a wide array of safety assessment programs. His expertise spans preclinical safety assessment studies, and regulatory-compliant toxicology for both small and large molecules.

Before joining Altasciences, Nazar was a Research Scientist at Charles River Laboratories for three year,s where he oversaw complex preclinical programs and worked closely with multidisciplinary teams to ensure regulatory alignment and scientific accuracy. He also contributed to innovative research initiatives, including an organ-on-a-chip project aimed at developing microphysiological systems to better model human responses to new therapeutics. Earlier in his career, he taught immunology and human anatomy at Northeast Ohio Medical University.

Nazar earned his doctorate in Biomedical Sciences, specializing in Cellular and Molecular Biology, from Kent State University, OH, where his research explored the regulatory roles of TRAPPC9 and L-Plastin in osteoarthritis. He has authored numerous peer-reviewed publications in the fields of bone biology, osteoarthritis, and regenerative medicine. Outside of his professional responsibilities, Nazar is an active member of several scientific societies, including the American College of Toxicology (ACT).



Justin Ulrich-Lewis, PhD

Study Director, Scientist

Justin Ulrich-Lewis joined Altasciences in 2025 as Study Director, Scientist. Justin has directed GLP and non-GLP Toxicology and pharmacology studies that have supported lead candidate selection as well as IND applications for small molecules, large molecules, and gene therapies.

Prior to joining Altasciences, Justin was a discovery scientist, responsible for leading pharmacology and toxicology studies in large animal models, which resulted in a successful IND filing with the FDA, as well as multiple conference presentations and publications.

Justin completed his doctorate at the University of Washington Medical School, where he studied vaccine and adjuvant immunology as well as nucleic acid-based vaccine development. During his graduate and postdoctoral training, he developed and screened vaccines against Influenza, Valley Fever, and SARS-CoV-2 *in vitro* and *in vivo* under BSL3 conditions.

Joel Skivington, MS, BS

Associate Scientist, Study Director

Joel Skivington joined Altasciences in 2025 as a study director. Before joining Altasciences, he developed extensive GxP experience across both industry and academia. He spent three years at Sanofi Pasteur supporting quality control laboratory operations, data integrity, and regulatory compliance, including the authoring and revision of SOPs, laboratory protocols, and data documentation processes.

In his nine years as a Professor of Chemistry at Keystone College and Luzerne County Community College, in Pennsylvania, he designed and taught both lecture and laboratory courses. Additionally, Joel spent two years with a community outreach center where he rebuilt and modernized their GED mathematics program. Joel carries this multidisciplinary foundation into his work as a study director, ensuring the same commitment to structure, integrity, and scientific rigor that has defined his career.

Tyler Lilie, MBS

Associate Scientist, Study Director

Tyler Lilie joined Altasciences as a study director in 2025, where he leads both GLP and non-GLP preclinical toxicology studies. He earned his Master of Biomedical Science from Geisinger College of Health Sciences, PA. He oversees research involving small and large animal models across a variety of dosing routes.

Prior to joining Altasciences, Tyler worked as a research technician in Boston, MA, focusing on HIV cure research.

KEY CLINICAL RESEARCH EXPERTS

- Ingrid Holmes, Vice President, Global Clinical Operations
- Beatrice Setnik, PhD, Chief Scientific Officer
- Mel Affrime, PharmD, Scientific Advisor, Translational Medicine
- Amy Denvir, Senior Director, Deployment and Integration
- Melanie Barth, BA, Director, Scientific Project Management
- Jeremy Mussallem, BS, Director, Scientific Project Management
- Aditya Martowirogo, MHSc, Associate Director, Scientific Project Management
- Daniel Bustillo, MBA, BA, Senior Director, Scientific Project Management
- Matthew Logan, General Manager, Clinical Operations
- Dr. David Nguyen, MD, MBA, General Manager and Co-Medical Director
- Dr. David Y. Kim, MD, Vo-Medical Director, Principal Investigator
- Dr. Gaetano Morelli, MD, Executive Vice President Medical Affairs, Chief Medical Officer
- Dr. Debra Kelsh, MD, Senior Principal Investigator
- Dr. Éric Sicard, MD, Senior Principal Investigator

MORE CLINICAL RESEARCH EXPERTS on next page

KEY CLINICAL RESEARCH EXPERTS

- Lester Galan, Executive Director, Clinical Trial Management
- Dr. William Foster, PhD, MD, Principal Investigator
- Dr. Colleen Harrison, MD, Principal Investigator
- Dr. Brett Smith, MD, MPH, MBE, Principal Investigator
- Kevin Noble, Senior Director, Laboratory Operations
- Kevin Kirkcaldy, BPharm, MBA, PharmD, Director, Pharmacy Operations
- Andy Pham, PharmD, Director, Pharmacy
- James Brazeal, General Manager, Clinical Operations
- Dr. Nadine Mokhallati, MD, Medical Director

Ingrid Holmes

Vice President, Global Clinical Operations
Montréal, QC

Ingrid Holmes joined Altasciences in 2011 as Vice President of Clinical Operations for the Montréal site. Now, as Vice President, Global Clinical Operations, Ingrid's responsibilities include oversight of all our clinical pharmacology units. Additionally, Ingrid is responsible for the harmonization of clinical processes across Altasciences' sites, and acts as Global Compliance Lead within the Quality Management System.

Ingrid started her career in clinical research in 1995 at LAB Pharmacological Research. Over the years, she has held various management roles in early-stage clinical operations, progressing to become Director of Business Operations and Continuous Improvement; overseeing the financial and quality performance of five international clinical sites.

In her various roles, she has gained extensive experience in the conduct of early-phase trials, international regulatory requirements, business operations, quality management systems, and Lean Six Sigma. Prior to joining Altasciences, Ingrid provided consulting services for early-stage CROs, and has successfully implemented company-wide management systems, including financial, client services, and operational KPIs in a number of organizations.

Beatrice Setnik, PhD

Chief Scientific Officer
Raleigh, NC

Beatrice Setnik, PhD, joined Altasciences in 2019, and has been working in clinical drug development and abuse potential assessment since 2005. She earned a doctorate in Pharmacology and the Collaborative Program in Neuroscience from the University of Toronto—where she currently works as an Adjunct Professor. In her former role as Vice President of Scientific & Medical Affairs at INC Research/inVentiv Health, she was responsible for scientific input on early-phase clinical trials, and in strategic initiatives in business growth and development.

In her previous role, Dr. Setnik led the clinical development, regulatory filing, and lifecycle management, including abuse potential evaluation of several pain compounds, including abuse-deterrent opioid formulations. Prior to which, she worked as a research scientist in Toronto, Canada, and was responsible for providing scientific input on various specialty Phase I/II clinical trials—including abuse potential studies for CNS drugs. Dr. Setnik has published numerous research articles in internationally recognized peer-reviewed journals, and is a peer-reviewer for manuscripts submitted to Pain Medicine and Drug and Alcohol Dependence.

An active member and participant in several congresses, including the College on Problems of Drug Dependence, Dr. Setnik has also been engaged in many aspects of abuse potential assessment, including development of patient reported outcome instruments, and contributing to post-marketing surveillance studies.

In 2024, Dr. Setnik was recognized as a PharmaVoice 100 winner, and named one of the 30 Most Influential People in the Pharma Industry by The Medicine Maker.

Mel Affrime, PharmD

Scientific Advisor,
Translational Medicine
Los Angeles, CA

Mel Affrime has an extensive background in global clinical research and development. Following completion of PharmD training at PCP&S in Philadelphia, he completed a Clinical Pharmacology Fellowship with Marcus Reidenberg, MD, at Temple University College of Medicine. He then co-founded the clinical pharmacology research unit at Hahnemann Hospital, Philadelphia, PA, with David Lowenthal, MD, PhD, in 1976. Mel remained on the faculty at Hahnemann until 1982, when he joined Hoechst-Roussel Pharmaceuticals as Associate Director, Clinical Pharmacology.

Prior to joining Altasciences in 2011 as Senior Vice President of Translational Medicine, Mel managed the medical staff at ICON Development Solutions' three CPUs, the Population PK software business, and the Research and Development department from 2006 to 2011. His experience also includes heading the Global Profiling Clinical Pharmacology department at Novartis Pharmaceuticals, and 16 years at Schering-Plough Research Institute where he managed the early development programs for the entire Schering pipeline.

Amy Denvir

Senior Director,
Deployment and Integration
Kansas City, KS

Amy Denvir joined Altasciences in 2018 as Director, Integration and Deployment. Having started her clinical research career in 1991 at Harris Laboratories (now Celerion), Amy held various management roles in early- and late-stage clinical operations, including Senior Director, Clinical Operations, overseeing the financial and quality performance of multiple research sites.

She has extensive experience in conducting early- and late-phase trials in healthy normal and patient populations, as well as in business operations, quality management systems, and systems designs and implementation, including eSource and training platforms.

Melanie Barth, BA

Director,
Scientific Project Management

With over 25 years of experience in early-phase clinical research, Melanie Barth joined Altasciences in 2014. She is renowned for her deep understanding of sponsor needs, working closely with the project management team to consistently exceed expectations.

Melanie's career highlights include significant contributions to clinical operations, project management training programs, and risk management strategies. She has provided meticulous oversight of trial master files (TMFs) and has led project managers, project coordinators, and TMF specialists to ensure seamless execution and compliance throughout clinical trials. Melanie champions a collaborative and proactive approach to project management, emphasizing continuous improvement and client satisfaction. Her dedication to advancing early-phase clinical research methodologies is unwavering, and she remains committed to fostering a culture of excellence and innovation within her team.

Jeremy Mussallem, BS

Director, Scientific Project Management

Jeremy Mussallem joined Altasciences in January 2013, and plays a pivotal role in overseeing clinical and CDMO projects as Associate Director of Scientific Project Management. With over 11 years of expertise in strategic project and program leadership encompassing early-stage drug development, CDMO manufacturing, and clinical operations, Jeremy oversees the CDMO project management group and supervises several clinical project managers.

Jeremy has a wealth of experience in managing diverse projects and demonstrating exceptional problem-solving abilities to resolve complex issues and ensure seamless project execution. He holds a Bachelor of Science from Bloomsburg University, PA.

Aditya Martowirogo, MHSc

Associate Director,
Scientific Project Management

Aditya Martowirogo joined Altasciences in 2020. Prior to that, he was a project manager at an oncology-focused biotech startup and developed and implemented quality improvement and patient safety projects in several hospitals across Toronto, Canada. Aditya obtained his Bachelor of Applied Science in Engineering Science, and a Master of Health Science in Clinical Engineering from the University of Toronto, Canada.

In his current role, Aditya leads various clinical project teams, manages key internal and external relationships, and drives intra- and inter-departmental quality improvement initiatives.

Daniel Bustillo, MBA, BA

Senior Director,
Scientific Project Management

Daniel Bustillo joined Altasciences in 2023 and has over twenty years' experience as a leader in project management, primarily at clinical CROs. Prior to joining Altasciences, Daniel served as the director of U.S. project management for a global early-phase CRO. Prior to that, he led teams through all phases of research and managed project teams at two technology companies.

Daniel is a graduate of Georgetown University, DC, and holds a Master of Business Administration from the University of Miami, FL.



Matthew Logan

General Manager, Clinical Operations
Montréal, QC

Matthew Logan joined Altasciences in 2011, and currently holds the role of General Manager, Clinical Operations, of Altasciences' clinical pharmacology unit in Montréal, QC. In partnership with Altasciences' quality assurance team, he has successfully hosted multiple regulatory audits, year after year. Matthew started his career in the Microbiology department of the Royal Victoria Hospital, before joining a large Montréal-based CRO. Over the course of 15 years, Matthew held various positions of increasing responsibility, culminating in his leading and collaborating with cross-functional project teams as Clinic Operations Manager.

With close to 25 years of experience in clinical research, Matthew understands the needs of sponsors, and works closely with them to meet (and exceed) expectations, regulatory requirements, and overall business objectives.



Dr. David Nguyen, MD, MBA

Co-Medical Director
and General Manager
Los Angeles, CA

Dr. David Nguyen is an anesthesiology-trained general manager and medical director, with experience in all major inpatient surgical specialties, including neurosurgery, cardiothoracic, and obstetrics, as well as outpatient procedures and GI services. He is intimately familiar with transfusion medicine, fluid management, infusion reactions, and emergency anaphylactic airway response.

While treating chronic pain patients, David received a first-hand account of both the opioid crisis, as well as the frustrations and poor quality of life for a patient suffering from chronic pain, which was the impetus that drove him to become a patient advocate for responsible medical cannabis use. At Altasciences, his goal is to push forward high-quality pharmaceutical therapies for patients, and to ensure subject safety on all trials.

Prior to joining Altasciences in 2017, he expanded his clinical knowledge to include dermatology and regenerative medicine, prompting the launch of his medical aesthetic practice, Dr. Dave's Dermal Institute, where he functioned as both medical director and primary practitioner. He brings the same customer-focused approach from this practice to volunteers in clinical trials, ensuring subject satisfaction at all levels.

Dr. David Kim, MD

Co-Medical Director, Principal Investigator
Los Angeles, CA

Dr. David Kim is a urology-trained principal investigator with a background in oncology research. He received a Bachelor of Science in Public Health from the University of Pennsylvania, and a Doctor of Medicine with honors distinction from George Washington School of Medicine. He has provided care for patients with core and advanced genitourinary conditions, including prostate cancer, bladder cancer, kidney cancer, complex urinary stones, infectious diseases, sexual dysfunction in men, urinary incontinence, voiding dysfunction, and enlarged prostate.

He is proficient in performing routine urologic surgical procedures, cystoscopy, prostate biopsy, and ureteral stent placement. David has worked at the National Institute of Health Cancer Institute, QC, and has been involved in the publication and presentation of multiple early clinical trials for oncology research.

At the Children's Research Institute Center for Neuroscience, he conducted extensive translational clinical research primarily focused on neural stem cells. He has also participated in sleep disorder research at the University of Pennsylvania Center for Sleep. Dr. Kim joined Altasciences in 2020 to integrate his diverse clinical and research experience to continue the advancement of impactful pharmaceutical therapies, by integrating his diverse experience in clinical and research with his passion for patient care.

Dr. Gaetano Morelli, MD

Executive Vice President Medical Affairs,
Chief Medical Officer
Montréal, QC

Dr. Gaetano Morelli joined Altasciences in 2017 as a medical advisor/consultant for complex studies. He quickly transitioned to Clinical Principal Investigator before becoming Chief Medical Officer in 2020.

He is a member of the Collège des Médecins du Québec, a Fellow of the Royal College of Physicians of Canada, certified in Internal Medicine and Gastroenterology, and a Fellow of the American College of Gastroenterology.

Gaetano has over 30 years of medical-clinical experience, and 25 years of experience in clinical research. He is a clinical academic gastroenterologist at the McGill University Health Network, and an associate professor of medicine at McGill University, QC—involved in medical training of students, residents, and specialty fellows. Previously, he was Director of Global Medical Affairs (CMO) at MDS Pharma for 10 years, overseeing five clinical sites in Canada, the United States, and Ireland.



Dr. Debra Kelsh, MD

Senior Principal Investigator
Kansas City, KS

Dr. Debra Kelsh has been with Altasciences' Kansas City facility since its founding in 2001. She worked concurrently as Assistant Clinical Professor in the Department of Psychiatry and Behavioral Sciences at the University of Kansas Medical Center for 11 years from 1996 until 2007. In 2007, she joined Altasciences' team full time. She has been board certified by the American Board of Psychiatry and Neurology since 1998.

Debra is a graduate of the University of Kansas School of Medicine and is a member the Alpha Omega Alpha Honor Medical Society.



Dr. Éric Sicard, MD

Clinical Principal Investigator
Montréal, QC

Dr. Éric Sicard has been with Altasciences since 2002 in positions of increasing responsibility, and currently holds the position of Clinical Principal Investigator. He is a member of the Collège des médecins du Québec, with 30 years' experience in the medical field.

Éric's well-rounded background includes academics, emergency medicine, geriatric and palliative care, and family medicine.

Lester Galan

Executive Director, Clinical Trial Management
Los Angeles, CA

Lester Galan has been with Altasciences for over 20 years, bringing hands-on operational experience through his time as a Clinical Research Coordinator, in both early and late phase clinical trials. Lester is a certified clinical research coordinator through the ACRP, which allows him to stay abreast on all the latest industry trends and guidance, while instilling his vast knowledge to those he manages and interacts with daily at the Phase I Unit.

Throughout his career, Lester has overseen multiple departments with an “on the floor” perspective, which has been paramount to Altasciences’ success. Lester currently leads the Phase I Unit, and is responsible for the screening, clinical operations, clinical trial management, and the clinical data processing departments.



Dr. William Foster, PhD, MD

Principal Investigator
Montréal, QC

Dr. William Foster joined Altasciences in 2018. He has extensive experience in both preclinical and clinical research with an emphasis in ophthalmology, including nanotechnology research.

A physician-scientist and practicing vitreoretinal surgeon, William actively leads clinical research studies and consults with clients about how to best achieve their desired milestones. A graduate of Caltech, Harvard, and Duke with training at Harvard Medical School, Washington University in St. Louis, MO, and UCLA, CA, he has held faculty positions at a number of research universities. As a bioengineer, he enjoys interdisciplinary collaboration.

Dr. Colleen Harrison, MD

Principal Investigator
Kansas City, KS

Dr. Colleen Harrison joined Altasciences in 2019, as Clinical Sub-Investigator, becoming Principal Investigator in January 2022. She received her Doctor of Medicine from Harvard Medical School in 2009. Since then, she has been practicing family medicine in various clinic and hospital settings in the U.S.A. and Canada.



Dr. Brett Smith, MD, MPH, MBe

Principal Investigator
Los Angeles, CA

Dr. Brett Smith is an internal medicine and preventive medicine-trained physician clinical investigator with extensive experience in adult primary care, outpatient medicine, epidemiology, and bioethics. He is well-versed in a broad range of therapeutic agents and disease states, including cardiology, gastroenterology, pulmonary, infectious disease, allergy, dermatology, endocrinology, and preventive care. Brett joined Altasciences in 2021 to make an impact at scale in pharmaceutical therapies. He brings clinical rigor with a dedication to patient safety and ethics to studies.

Brett earned a Bachelor of Science in Genetics from Rutgers University, a Doctor of Medicine from the UMDNJ-Robert Wood Johnson Medical School, Master of Bioethics from the University of Pennsylvania, PA, and a Master of Public Health, with a focus on epidemiology, from the University of California, Berkeley.

Kevin Noble

Senior Director, Laboratory Operations
Los Angeles, CA

Kevin joined Altasciences in 2013 as Laboratory Coordinator, Laboratory Supervisor, and Research Laboratory Manager, before taking on the role of Senior Director. Kevin is responsible for the integrity of the sample collection and preparation in the pharmacokinetic laboratory, and currently oversees the Clinical Safety Laboratory and Cell Isolation (PBMC) Laboratory in Los Angeles.

Kevin has a strong background in laboratory management, operations efficiency, and vendor contract negotiation, in addition to hosting several CAP, CLIA, and COLA audits. He has worked on clinical research studies covering a wide range of therapeutic areas including allergy/asthma, cardiology, dermatology, device studies, endocrinology, gastroenterology, healthy patient studies, hematology, infectious diseases, neurology, obstetrics/gynecology, ophthalmology, otolaryngology, pain management, pharmacology, toxicology, pulmonary/respiratory, and rheumatology.

Kevin Kirkcaldy, BPharm, MBA, PharmD

Director, Pharmacy Operations
Montréal, QC

Kevin Kirkcaldy, BPharm, MBA, PharmD, joined Altasciences in 2019, bringing with him over 18 years of experience as a licensed pharmacist in retail pharmacy, business management, and clinical research. As head of the pharmacy department, he oversees all activities related to IMP management, including quality control, compounding, aseptic technique, and controlled substance management. By working closely with clients, he and his team ensure optimal and timely pharmacy services that are adapted and personalized for different study designs and needs.

Kevin has a Bachelor of Science and a PharmD in Pharmacy, a Master of Business Administration in Pharmaceutical Management, and a graduate degree in Pharmaceutical Product Development.



Andy Pham, PharmD

Director, Pharmacy
Los Angeles, CA

Andy Pham has over 20 years of pharmacy experience, including a decade in clinical research and investigational drugs. He utilizes his strong educational background and experience in study drug management to ensure Altasciences' adherence to GCP, and all applicable laws and regulations. Andy is a hands-on and knowledgeable team leader, who is well-respected for his dedication and professionalism.

Skilled at training staff on new investigational drugs, and proper procedures for storage, administration, and the recording of data, he also provides essential expertise in communications with clients and regulatory committees, as well excellent support to study investigators and nurses to ensure patient safety and the integrity of our studies.

James Brazeal

General Manager, Clinical Operations
Kansas City, KS

James joined Altasciences in 2023, having previously worked as Vice President of Research at Akron Children's Hospital, and most recently as Vice President of Research Operations for Circuit Clinical—an integrated research organization bringing clinical trials to local communities. With a Bachelor of Science in Biology from Kansas State University, KS, and close to a decade of experience in the healthcare and pharmaceutical sectors, James uses his robust knowledge of clinical research to oversee the day-to-day management of clinical operations at Altasciences' Kansas site.

In another life, James graduated from the University of Missouri-Kansas City School of Law, with a Doctor of Law degree (JD), and is a licensed attorney in the state of Missouri—as well as being a registered U.S. Patent Attorney. James has a personal drive to improve outcomes, experience, and quality for patients, along with a deep passion for research.

Dr. Nadine Mokhallati, MD

Medical Director
Kansas City, KS

Dr. Nadine Mokhallati, MD, joined Altasciences in 2024 as Co-Medical Director of the Kansas site. Prior to this, she worked as a Pediatric Pulmonologist at Children's Mercy Hospital in Kansas City, MO, where she also served as medical director of the Pulmonary Function Lab, and Medical Director of their School Based Asthma Telemedicine program. She also held the role of Assistant Professor of Pediatrics at the University of Missouri Kansas City and University of Kansas.

Nadine obtained her Doctor of Medicine in 2009 from the American University of Beirut. After moving to the U.S. in 2009, she completed a postdoctoral program at Cedars Sinai Medical Center in Los Angeles, her residency through the University of Arizona, and a fellowship at Cincinnati Children's Hospital Medical Center. She has also obtained certification in Clinical and Translational Research from the University of Cincinnati.

Nadine has received numerous research grants and contracts and served as both principal investigator and sub-investigator for research projects sponsored by the NIH, the National Heart, Lung, and Blood Institute, charitable foundations, and pharmaceutical sponsors.

KEY BIOANALYTICAL EXPERTS

- Lynne Le Sauteur, PhD, Vice President, Laboratory Sciences
- Anahita Keyhani, PhD, Senior Director, Scientific Operations, Mass Spectrometry
- Danielle Salha, PhD, Senior Director, Senior Director Global Immunology
- Kevork Mekhssian, MSc, Senior Scientific Director
- Milton Furtado, Scientific Director, Method Development
- Leighla Holmes, BA, Director, Bioanalytical Operations, Laboratory Services
- Jeff Plomley, MSc, Scientific Director, Method Development
- Jason Robinson, MS, Associate Director, Ligand Binding Assays
- Kaylyn Koenig, PhD, Associate Director, Molecular Biology
- Brandon Nichols, MS, BS, Associate Director, LC-MS
- Jean-Nicholas Mess, MSc, Principal Scientist, Method Development
- Mano Sahoo, MS, PhD, Director, Bioassay
- Mingluan Chen, PhD, Principal Research Scientist, Method Development
- Adam Martin, PhD, Principal Scientist, Laboratory Sciences

MORE BIOANALYTICAL EXPERTS on next page

KEY BIOANALYTICAL EXPERTS

- Martin Turcotte, PhD, Scientific Director, Flow Cytometry
- Quentin Osseman, Principal Scientist, Ligan Binding Assays
- Jean-François Dupuis, MSc, BSc, Senior Research Scientist, Method Development

Lynne Le Sauteur, PhD

Vice President,
Laboratory Sciences

Lynne Le Sauteur, PhD, joined Altasciences in September 2019, and leads a team of over 260 specialists involved in bioanalysis, immunogenicity, biomarkers, and immunotoxicity assessments for large and small molecules, oligonucleotides and gene therapy. She received a doctorate in Pharmacology and Therapeutics from McGill University and has over 20 years' experience in biologic drug development.

Prior to joining Altasciences, Lynne was Director of Downstream Processing and Analytics, as well as Program Leader, Biologics and Biomanufacturing, for the Human Health Therapeutics Research Center at the National Research Council of Canada (NRC). Here she led numerous teams and initiatives to discover, biomanufacturer, and characterize novel biologics for unmet needs in collaboration with different biopharmaceutical companies.

Before her time at the NRC, Lynne worked at Charles River Laboratories, where she established the Immunology Department, and led the scientific and strategic growth of that group from one to over 80 employees, effectively delivering expertise to sponsors in advancing numerous biologics through the drug development value chain.



Anahita Keyhani, PhD

Senior Director, Scientific Operations,
Mass Spectrometry
Laval, QC

Anahita Keyhani, PhD, joined Altasciences in 2015, and leads a team of over 30 scientists dedicated to method development and innovator regulated bioanalysis, clinical and preclinical. In addition to her role as a scientific and client relationship manager, she actively trains, coaches, and mentors scientists from cross-functional departments throughout Altasciences.

Anahita received her Bachelor of Science and Master of Science degrees from Ohio State University, with a doctorate from McGill University, and has over 20 years of CRO experience in regulated bioanalysis for preclinical and clinical development. Prior to joining Altasciences, her professional career was spent mainly within the bioanalytical group at Charles River Laboratories. She has also worked at Merck in Montréal as a senior scientist in pharmaceutical research and development and, during the pursuit of a Master of Science, participated in research and development projects for pediatric and adult nutritional products at Abbott Laboratories' Ross Product Division.

Anahita has authored or co-authored over 15 peer-reviewed publications and presented numerous posters and presentations in the bioanalytical domain. She actively participates in the Global CRO Council, a forum for CRO leaders to openly discuss bioanalysis and the regulatory challenges unique to the outsourcing industry.

Danielle Salha, PhD

Senior Director, Global Immunology,
Laval, QC

Danielle Salha, PhD, joined Altasciences in September 2017 as Director of the Ligand Binding Assay Department and was promoted to Senior Director, Global Immunology in 2024. She leads a team of 45 scientists, QCs, and analysts dedicated to method development, validation, and sample analysis to support preclinical and clinical PK, PD, and immunogenicity studies.

Danielle has over 20 years pharmaceutical and CRO experience in bioanalysis supporting drug development from preclinical to Phase I and II clinical studies, including vaccines, monoclonal antibodies, ADCs, and Oligonucleotides. She has authored and co-authored several peer-reviewed publications and is an inventor, with four patent applications to her credit. She received a Bachelor of Science from the University of Montréal, and a doctorate at McGill University from the Department of Immunology and Microbiology.

Kevork Mekhssian, MSc

Senior Scientific Director,
Laval, QC

Kevork Mekhssian joined Altasciences in 2013. He has over 15 years of pharmaceutical and CRO experience in mass spectrometry-based characterization and quantitation of biotherapeutic proteins using LC-MS and hybrid LBA-LC-MS workflows.

He has actively participated in setting up high-throughput biotherapeutic quantitation methods and has greatly contributed to establishing Altasciences as an industry leader in this field. Kevork has authored and co-authored several peer-reviewed publications and presented at numerous bioanalytical and mass spectrometry international meetings. Kevork completed a Master of Science in Biochemistry at Concordia University in Montréal, Canada.

Milton Furtado

Scientific Director, Method Development
Laval, QC

Milton Furtado joined Altasciences in 2007. He has over 25 years of experience in bioanalysis in the pharmaceutical industry. Milton has worked in the preclinical and clinical environments and has developed over 300 LC-MS/MS assays. Over the years, Milton has been a key asset in overcoming bioanalytical challenges and providing scientific direction in the CRO industry.

Milton has published over 25 journal articles, and peer-reviewed multiple scientific papers. He received his Bachelor of Science in Chemistry from Concordia University in Montréal, Canada.



Leighla Holmes, BA

Director, Laboratory Services

Leighla Holmes joined Altasciences in 2025 as Director, Laboratory Sciences, bringing extensive experience in supporting clinical development (Phases I–IV) with biomarker and bioanalytical strategy. She started her career in bioanalytical chemistry, assay development, and biomarker research, and went on to develop the biomarker bioanalytical outsourcing department for Ionis Pharmaceuticals. With a background in both clinical and non-clinical programs, she has led teams in GLP-compliant assay development, technical support, and in-house validations, ensuring operational excellence across complex laboratory environments.

Leighla holds dual Bachelor of Arts degrees in Neuroscience and Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder, where she contributed to novel RNA-guided therapeutics research. Known for her leadership, training, and cross-functional collaboration, she excels at connecting scientific insight to operational strategy, driving both team performance and impactful research outcomes.



Jeff Plomley, MSc

Scientific Director, Method Development
Laval, QC

Jeff Plomley began his research career in the Gas Phase Ion Chemistry Laboratory of Prof. Raymond E. March as a research scientist designing novel ion trap scan functions to support applications development. He then joined Thermo Instruments Canada as an Applications Marketing Chemist, then SCIEX as a Senior Scientist in Product Definition and Core Research. Jeff has worked in both the preclinical and clinical CRO environment since 2001, developing over 250 de novo LC-MS/MS assays.

He has contributed to the publication of over 25 peer-reviewed papers, 70 scientific posters and technical publications, holds patents on MS instrumentation, and frequently blogs and presents on microsampling workflows and advanced MS techniques. Jeff's current research interests include applications development involving ion-mobility spectrometry, and the implementation of microsampling technology into patient-centric medical devices. Jeff holds a Master of Science in Chemistry from Queens University in Kingston, Ontario, Canada.



Jason Robinson, MS

Associate Director,
Ligand Binding Assays

Jason Robinson joined Altasciences in June 2025 as the Associate Director of the Ligand Binding Assay (LBA) team—with a focus on streamlining processes, enhancing cross-functional collaboration, and ensuring the successful execution of sponsor-driven non-clinical trials. Jason oversees daily operations, supports project delivery, and promotes a culture of continuous improvement within the LBA team.

Prior to joining Altasciences, Jason spent eight years at PPD as a principal investigator and manager, where he led end-to-end execution of pharmacokinetic (PK) and biomarker programs, from method development and validation to sample analysis. His leadership in sponsor-driven research has played a key role in accelerating timelines and maintaining scientific integrity across complex studies.

Jason holds a Master of Science in Molecular Biology and Genetics from Virginia Commonwealth University, which has shaped his analytical approach to scientific research and data interpretation.

Kaylyn Koenig, PhD

Associate Director, Molecular Biology

Kaylyn Koenig first joined Altasciences in 2019 as a scientist and was promoted to Principal Scientist in 2023. In her current role, Kaylyn assists PCR scientists with their projects and helps them identify tools and craft custom laboratory solutions to meet sponsors' needs. Kaylyn collaborates closely with the business development team and is always happy to speak with potential clients about what makes Altasciences a different kind of CRO/CDMO.

Kaylyn graduated from Texas A&M University with a Bachelor of Science in Marine Biology, holds a Doctor of Philosophy in Environmental Toxicology from Texas Tech University, and completed a professional certificate in Biomedical Regulatory Affairs at the University of Washington.



Brandon Nichols, MS, BS

Associate Director, LC-MS

Brandon Nichols joined Altasciences in June 2025 as Associate Director, LC-MS, bringing extensive experience in analytical chemistry and method development for both small and large molecules. Over his career, he has supported diverse projects across multiple platforms, including LC-MS/MS, LC-MS/Q-TOF, and ion chromatography, while leading cross-functional teams and coordinating with stakeholders to ensure seamless project execution.

With a Master of Science in Chemistry from UC San Diego, and a Bachelor of Science from UC Irvine, Brandon combines technical expertise with a collaborative approach, driving innovation and efficiency in bioanalytical workflows. Known for his passion for mentorship and cross-team communication, he excels at training analysts, optimizing laboratory processes, and connecting scientific insights to business objectives.

Jean-Nicholas Mess, MSc

Principal Scientist,
Method Development
Laval, QC

Jean-Nicholas joined Altasciences as Method Development Scientist in 2004, after obtaining a Master of Science in Biochemistry from the University of Montréal. Over the years, Jean-Nicholas has shown a growing interest in biotherapeutic protein quantitation using LC-MS and hybrid LBA-LC-MS approaches, and has authored several publications and posters on the subject.

With a strong background in bioanalytical method development and troubleshooting, Jean-Nicholas has actively participated in devising biotherapeutic quantitation workflows, and has been a key contributor in the establishment of Altasciences as an industry leader in this field. In his current role as Principal Scientist, Jean-Nicholas is responsible for providing scientific support, technical leadership, and guidance throughout assay development, validation, and sample analysis.

Mano Sahoo, MS, PhD

Director, Bioassay
Columbia, MO

Mano Sahoo, MS, PhD, joined Altasciences in November 2021. He oversees the overall scientific, regulatory, and operational needs of the bioassay department at our preclinical site in Columbia, MO. Mano is an immunologist with more than 17 years of experience in both academic and GLP-regulated CRO environments involving studies related to preclinical drug development, immuno-oncology, and host-pathogen interactions.

Prior to joining Altasciences, He worked as a Senior Scientist at Envigo/Covance and was later promoted to Site Scientist Lead/Manager to lead the Immunology and Immunotoxicology group.

Mano received a Bachelor of Science and Master of Science in India, obtained his doctorate in Microbiology (Immunology) from the University of Mississippi Medical Center, and completed postdoctoral training from Chicago Medical School, IL.

Mingluan Chen, PhD

Principal Research Scientist,
Method Development

Mingluan Chen, PhD, joined Altasciences in 2014, and is a principal scientist in the LC-MS method development group. He received a doctorate in Analytical Chemistry from Wuhan University, China, focusing on the characterization of phytohormones using microscale LC-MS. He has developed over 100 de novo bioanalytical assays by LC-MS, for both small and large molecules.

Mingluan has authored more than 20 peer-reviewed articles and has contributed to numerous scientific posters and presentations. More recently, one of his key objectives has been the establishment of novel LC-MS-based strategies and workflows for the quantitative bioanalysis of oligonucleotide therapeutics.



Adam Martin, PhD, MS

Principle Scientist,
Laboratory Sciences,
Columbia, MO

Adam Martin, PhD, MS, has been with Altasciences since 2019. He has brought with him over a decade of experience managing an academic production and research lab for DNA cloning and cell-based assays.

Adam established the initial bioassay capabilities at Altasciences, and is still a contributing member of the team while overseeing the clinical pathology and test materials (pharmacy) groups within laboratory services.

He received a Master of Science in Applied & Environmental Biology, a doctorate in Chemistry from the Missouri University of Science & Technology, and postdoctoral training at University of Missouri, focusing on flow cytometry.

Martin Turcotte, PhD

Scientific Director, Flow Cytometry
Laval, QC

Martin Turcotte, PhD, joined Altasciences in 2023. Bringing with him more than 13 years of scientific experience and a keen interest in health sciences, Martin's initial role was Scientific Liaison, before transitioning to his current position as Scientific Director, Flow Cytometry. Following the completion of a Doctor of Philosophy in Pharmaceutical Sciences from the Université de Montréal, and several years in the CRO industry, he has developed extensive expertise in flow cytometry technologies.

Martin is always enthusiastic to share his knowledge, and help Altasciences' partners improve the quality of their drug development programs.

Quentin Osseman, PhD, MSc, BSc

Principal Scientist,
Ligand Binding Assays
Laval, QC

Quentin Osseman joined Altasciences in 2022, and currently serves as a principal scientist, leading a team dedicated to developing or transferring and optimizing immunogenicity ligand-binding assays and cell-based assay to support both GLP and non-GLP studies. With a strong foundation in virology and immunology, and over five years of postdoctoral research at the Centre de recherche du CHUM, Quentin brings deep scientific rigor and strategic insight to every program. His expertise spans method development, and cross-functional collaboration, ensuring the delivery of robust, high-quality bioanalytical data to sponsors.

Before joining Altasciences, Quentin earned his doctorate in Microbiology and Immunology from the Université de Bordeaux, France. Passionate about scientific innovation and team leadership, he thrives in dynamic environments that challenge convention and drive continuous improvement in drug development.

Jean-François Dupuis, MSc, BSc

Senior Research Scientist,
Method Development
Laval, QC

Jean-François Dupuis is a Senior Research Scientist in Method Development who joined Altasciences in 2015. He leads the design and optimization of analytical methods for the quantitation of biotherapeutics, including antibodies, peptides, oligonucleotides, and antibody-drug conjugates (ADCs), using LC-MS. Having worked for over ten years at Altasciences, he has developed deep expertise in biochemistry and molecular biology, particularly in hybrid ligand-binding LC-MS and solid-phase extraction techniques within a regulated environment.

Jean-François is highly experienced in enzyme and immunological assays and plays an active role in troubleshooting analytical challenges, supporting GLP validations, and mentoring junior scientists. He holds a Master of Science in Molecular Biology from Université de Montréal and a Bachelor of Science in Biochemistry from The Université du Québec à Montréal, QC, and his research on advanced LC-MS bioanalytical methods has been published in several leading journals.

KEY CRO SERVICES EXPERTS

- Nicole Maciolek, PhD, Executive Vice President, CRO Services
- Kristen Fitzpatrick, Executive Director, Data Analysis and Reporting
- Cynthia Marie Fazio, Associate Director, Medical Writing
- Catherine Dussault, Senior Director, Scientific and Regulatory Affairs
- May Kansou, BSc, Associate Director, Regulatory Affairs and Submissions
- Sophie Boudriau, PhD, Senior Principal Scientist, Scientific Affairs
- Denise Milovan, PhD, MA, CPsych, Senior Neuroscientist, Neuropsychologist
- Scott Ward, Senior Director, Biostatistics and Programming
- Roland Jbeily, Manager, Regulatory Affairs
- Hazel Clay, Scientific Advisor, Drug Development
- Peter Varney, Pharma Development and Strategy Advisor
- Pete Gaskin, PhD, BSc (Hons), Scientific Advisor, Drug Development
- Laurianne Bessiere, PhD, Process Improvement Manager

Nicole Maciolek, PhD

Executive Vice President, CRO Services

Nicole Maciolek, PhD, joined Altasciences in June 2018,and oversees data management, biostatistics, programming, medical writing, and pharmacology operations. She started her career in clinical research in 2007 and has held various roles in early clinical research across project management, data management, biostatistics, pharmacokinetics, and medical writing including overseeing operations, process, and quality for all aspects of data and reporting services.

Before joining Altasciences, Nicole was a director on the early clinical research team at DaVita Clinical Research, a niche contract research organization that specialized in patients with renal or hepatic impairment, where she gained a keen understanding of the effective design, clinical conduct, and reporting of studies in these specialty populations. She has a doctorate in Molecular Genetics from the Medical College of Wisconsin.

Kristen Fitzpatrick

Executive Director,
Data Analysis and Reporting

Kristen Fitzpatrick joined Altasciences in 2019, as Director of Medical Writing, bringing more than 13 years of CRO experience, and over seven years of leadership experience to the position. In 2021, she expanded her role to oversee the pharmacology department, helping to build a high-performing team and increasing support for preclinical studies. In 2023, her role grew again to include management of the data services organization, comprised of data management, biostatistics, and SAS Programming.

Kristen received her Master of Science degree in Molecular and Environmental Toxicology and began her career in preclinical study management, taking on roles of increasing responsibility before transitioning to early phase clinical project management and leadership.



Cynthia Marie Fazio

Associate Director, Medical Writing

Cynthia Marie Fazio started her career as a research scientist at McGill University, where she received a Master of Science in Developmental Biology. She has over 15 years of CRO experience, having worked previously as a study director in preclinical services and joining Altasciences' clinical operations team in 2006 as an assistant study manager. She later worked as a Clinical Research Scientist in the Scientific Affairs department for several years, managing various aspects of clinical trials and providing scientific support. In her current role as Manager of Medical Writing, she is responsible for overseeing and supporting the medical writing team in the preparation of high-quality study documents used in the context of sponsors' research programs.

In addition to her management role, Cynthia is also Lean Six Sigma Green Belt-certified and is actively involved in cross-functional improvement initiatives and quality management.

Catherine Dussault, BSc

Senior Director, Scientific and Regulatory Affairs

Catherine Dussault joined Altasciences in 2004. She has a Bachelor of Science in Biochemistry, and a post-graduate diploma in drug development. In her current role as Senior Director, Scientific Affairs, Catherine provides scientific leadership and a deep knowledge in regulatory work for various drug development clinical research programs.

Catherine has overseen over 2,000 clinical trials including single ascending dose (SAD), multiple ascending doses (MAD), food effect (FE), bioequivalence (BE), 505(b)2, drug-drug interactions, proof-of-concept (POC), and special patient population (renal and hepatic impairment, recreational drug users) studies. Catherine is enthusiastic and highly engaged with strong critical and scientific thinking skills. She promotes interdisciplinary work and collaboration between teams.

May Kansou, BSc

Associate Director,
Regulatory Affairs and Submissions

May Kansou joined Altasciences in 2025 and currently serves as Associate Director, Regulatory Affairs and Submissions, where she's responsible for leading regulatory submissions and providing guidance. With over 18 years of combined regulatory affairs experience in both a biopharmaceutical and CRO, May brings regulatory expertise to support the regulatory team in ensuring alignment with Health Authority requirements and facilitating successful interactions with clients and regulators.

May is motivated by a passion for helping others and advancing science. She holds a Bachelor of Science with a focus in analytical chemistry from Athabasca University, AB.

Sophie Boudriau, PhD

Senior Principal Scientist,
Scientific Affairs

Sophie Boudriau, PhD, joined Altasciences in 2013 as Senior Clinical Research Scientist, and has been in the CRO industry for more than 20 years. Her depth of knowledge was quickly recognized and she transitioned within the department to the research and development team (SRA R&D). In her current position, Sophie continues to expand her expertise and adapt her specialized capabilities to trial design development and optimization, as well as becoming highly proficient in conducting PK/PD non-compartmental analysis. She has extensive capabilities in the specialized areas of protocol development, data analysis, and regulatory documentation.

Sophie has applied her knowledge to writing a number of abstracts and presenting posters/publications at international conferences. She routinely reviews the evolving regulatory landscape for a wide range of regulatory agencies, such as the FDA, TPD, and EMA, and provides internal guidance to medical writers and pharmacokinetic scientists, as well as clients in support of their regulatory applications.

Denise Milovan, PhD

Senior Neuroscientist,
Neuropsychologist

Denise Milovan, PhD, joined Altasciences in 2020. In former roles at Syneos Health and DecisionLine Clinical Research, she provided expertise and oversight of Neurocognitive early-phase programs dedicated to the assessment of the pharmacodynamic effects of CNS drugs. She has a strong interest in the adaptation and refinement of traditional neurocognitive as well as behavioral measures for computerized administration tailored to the specific requirements of early-phase clinical trials. Denise practices clinical neuropsychology in a variety of settings, including hospitals (neurology, traumatic brain injury), non-profit organizations, and private practice.

She holds a doctorate and a Master of Science in Clinical Neuropsychology, and has also completed the requirements for a Master of Science in Clinical Pharmacology. As a member of the Council of the College of Psychologists of Ontario from 2015 to 2021, Denise held various roles, including that of Vice President.

Scott Ward

Senior Director,
Biostatistics and Programming

Scott Ward joined Altasciences in 2022, bringing with him 24 years of experience leading teams of biostatisticians and programmers in the pharmaceutical and CRO industry. Scott holds a degree in Business Management and Administration and embarked on his pharmaceutical career as a SAS programmer at Eli Lilly. During his time there, he gained valuable insights into the various stages of the clinical trial development process and honed his skills in leading studies from end-to-end.

Transitioning into the CRO industry, Scott focused on enhancing his technical expertise, particularly in late-phase oncology trials. His career progression led him into management, where he spent seven years at the forefront, spearheading a team of 300 in the strategic implementation of global resource management.

In his current role at Altasciences, Scott oversees the biostatistics and programming departments. His driving motivation is the desire to assist sponsors in discovering groundbreaking and vital new therapies. Scott emphasizes a value-added approach to the representation of robust statistical data analysis, ensuring high-quality outputs that meet regulatory agency requirements

Roland Jbeily

Manager, Regulatory Affairs

Roland joined Altasciences in 2020, bringing more than seven years of experience in regulatory affairs and compliance for global authorities, such as the FDA, EMA, and TGA, with an in-depth expertise in Health Canada's drugs and cannabis regulations. As Manager, Roland oversees clinical trial applications to Health Canada for small drug molecules, biologics, natural and cannabis health products, and combo drug-medical devices.

He provides sponsors with strategic guidance on regulatory strategies, gap analysis, consultancy support, and liaison support with Health Canada. He has experience in chemistry, manufacturing and control (CMC), and pharmaceutical manufacturing.

Roland began his career working in the Québec Lab at Pharmascience as a chemistry analyst. From there, he held positions at Accord Healthcare as a regulatory affairs specialist, and Canopy Growth Corporation as a CMC manager for cannabis research products.

He is a member of the Ordre des chimistes du Québec (Order of Québec Chemists) and a member of the DIA (Drug Information Association). He earned a Master of Science in Biochemistry from Université de Montréal and a D.E.S.S. in Biomedical Engineering from Polytechnique de Montréal. He has a certificate in Leadership from edX (Harvard University), and a certificate in good clinical practices (GCP).

Hazel Clay, PhD, BSc

Scientific Advisor, Drug Development

Hazel Clay, PhD, BSc, joined the Altasciences team in 2022 with over 30 years of experience supporting the development of innovator pharmaceutical assets.

Prior to that, she held a variety of different positions at Labcorp, from toxicology study director to head of study direction, where responsibilities included independent toxicology review for their UK clinic and ethics committee. She was a founder member of the program management service to accelerate clients through to first-in-human studies. Latterly she was Executive Director, Science and Strategy, for early-phase development solutions, leading a global team of drug development specialists. During this time, she was the industry lead for the nonclinical module at Leeds University Master's Course in Biopharmaceutical Development.

Hazel is passionate about providing bespoke solutions for biotech companies and supporting their goals through nonclinical development and transitioning to first-in-human studies through to clinical proof of concept. She has extensive experience in navigating the challenges of drug development.

Peter Varney

Pharma Development and Strategy Advisor

Peter Varney joined Altasciences in 2021 as Pharma Development and Strategy Advisor. Peter brings 40 years of experience in commercial development, strategic alliances, and relationship management from his previous roles at Covance (now Labcorp). His previous roles included Vice President, Strategic Partnering, and Vice President, Sales and Marketing. Initially trained as a toxicologist, his experience grew to encompass all areas of nonclinical, clinical pharmacology, and Phase II to IV clinical development.

In all roles, the objective was to create strategic value to all clients, ranging from emerging companies through to top 20 pharma. Peter is based in the UK and provides guidance to the strategic direction of Altasciences in Europe, through the provision of industry-leading programmatic approaches to drug development.

Pete Gaskin, PhD, BSc (Hons)

Scientific Advisor, Drug Development

Pete Gaskin, PhD, BSc, joined the Altasciences team in 2024, bringing over 30 years of experience in supporting the development of innovative biopharmaceuticals. Before joining Altasciences, he was the senior director and head of the global scientific advisory services team at Charles River Laboratories. He also served as a Principal at Aptuit Consulting and PPD, where he advised clients and the company on biopharmaceutical development strategy and due diligence. At Quintiles he led a team of experts managing complex global drug development projects from clinical proof of concept to market.

Prior to this, he held various positions in the life sciences and CRO industry, ranging from toxicology study director to senior toxicologist. Pete has presented at many international meetings and lectured on drug development at the Universities of Edinburgh, Napier, QMUL, and Porto.

Pete is passionate about providing tailored development strategies for innovative biological products and advanced therapies, supporting biotech companies' goals from nonclinical development to clinical proof of concept.



Laurianne Bessiere, PhD

Process Improvement Manager

Laurianne Bessiere, PhD, joined Altasciences in 2016 as an associate scientist in the scientific affairs team. In this role, she progressed within the team, working on increasingly complex studies and providing study design synopses for bioequivalence and Phase I studies, along with scientific guidance and support to both sponsors and internal teams.

In 2024, she transitioned to the role of Process Improvement Manager, focusing on enhancements to Compass, Altasciences' study management system. Her work aims to streamline processes and facilitate collaboration between Altasciences and its Sponsors.

Laurianne earned a Doctorate in Biology from Université Sorbonne-Paris-Cité, France, in 2015, where she studied the genetic mechanisms of a rare juvenile ovarian cancer. She is driven by a strong interest in improving the management of diseases with unmet medical needs and highlighting women's health challenges in clinical research.

KEY MANUFACTURING AND ANALYTICAL SERVICES EXPERTS

- Nasir Egal, General Manager, CDMO Services
- Anuji Abraham, PhD, MBA, Senior Director, Pharmaceutical Development, CMDO
- Scott Myslinski, BS, Director, Manufacturing
- Andrew Buis, BSc, MSc, Senior Formulation Scientist

Nasir Egal, PhD

General Manager, CDMO Services
Harleysville, PA

A senior executive with over 20 years of experience in the pharmaceutical industry, Nasir Egal joined Altasciences in 2024. Bringing with him a deep understanding of pharmaceutical regulations, Nasir has held various senior roles at prominent organizations, including Quotient Sciences, Sanofi, Novartis, and Merck. He also spent several years as a research scientist at the FDA.

Nasir holds a doctorate in Chemistry from the American University in Washington, D.C., as well as executive management certificates from IMD Business School in Lausanne, Switzerland, and Franklin W. Olin Graduate School of Business at Babson College in Massachusetts.

Anuji Abraham, PhD, MBA

Senior Director, Pharmaceutical Development, CMDO
Philadelphia, PA

Anuji joined Altasciences in 2025 as Senior Director of Pharmaceutical Development, leading pharmaceutical product development with a focus on building a scientifically rigorous team and laboratory that foster innovation and deliver meaningful impact for Altasciences and its clients.

Before joining Altasciences, Anuji spent 14 years at Bristol Myers Squibb, advancing through a series of leadership roles, including Associate Scientific Director, Senior Principal Scientist, and Team Leader for Drug Product Development. Her work has spanned materials science and engineering, biophysical characterization, and formulation development across multiple molecular modalities.

She earned her doctorate in Physical Chemistry from the Swiss Federal Institute of Technology (ETH Zurich), where she was an active member of the Swiss Chemical Society. She also studied at the London School of Economics and Political Science, focusing on business administration, management, and operations.

Anuji has authored or co-authored over 40 peer-reviewed publications and is recognized for her expertise in materials selection and analytical characterization. She is an active member of the American Association of Pharmaceutical Scientists (AAPS), where she helps lead the preformulation and formulation development community.

Scott Myslinski, Bs

Director, Manufacturing,
Harleysville, PA

Scott Myslinski joined the CDMO team in 2014 as a Manufacturing Associate. Throughout his early years at the CDMO site, Scott was able to apply his experience and skills to quickly grow within the company and was promoted to Manufacturing Manager in 2015.

After successfully managing the manufacturing group for several years Scott was eventually promoted to his current role as Director of Manufacturing in 2022. Scott has over 10 years of industry experience in manufacturing. Prior to joining Altasciences, he worked with another pharmaceutical manufacturing CDMO where he gained extensive experience and knowledge in his role.

Andrew Buis, BSc, MSc

Senior Formulation Scientist,
Harleysville, PA

Andrew Buis joined Altasciences in 2021, bringing over eight years of experience in designing and developing drug formulations from bench top to clinical trials. With previous experience at Lubrizol Life Sciences' CDMO Division and DSM Nutritional, Andrew is well-versed in a broad range of dosage forms, scaling up and optimizing processes for GMP production, and supporting GMP manufacturing.

Andrew began his professional career at Pennsylvania State University, Eberly College of Science, where he earned a Bachelor of Science in Biochemistry. He later received a Master of Science in Biotechnology from the University of South Florida, Morsani College of Medicine, in 2016.

KEY COMPLIANCE AND QUALITY ASSURANCE EXPERTS

- David Grégoire, Chief Quality and Compliance Officer
- Paul Sidney, Vice President, GLP Quality Assurance
- Natasha Savoie, Senior Director Quality, Clinical and Research Services
- Stephen Rogenthien, Senior Director Quality, CDMO

David Grégoire

Chief Quality and Compliance Officer

David joined Altasciences as Director, Quality Assurance, in 2012. In 2014, he was appointed Vice President, Quality Systems, with overall responsibility for the QA groups and the implementation of quality systems across the organization. In 2018, he became Vice President of Compliance and Regulatory Affairs. In 2021, he was appointed Chief Quality and Compliance Officer, his current role.

David started his career as a Quality Assurance Inspector at CTBR Bio-Research (now Charles River Laboratories) in 2000, where he progressed to QA Specialist in 2003. Prior to Altasciences, he worked at Pharmascience Inc.

As Manager of Clinical Quality Services, he implemented GLPs in a newly developed bioanalytical laboratory and designed a quality system for Altasciences' clinical outsourcing operations. David has been actively involved in the Canadian QA research community as a member of the Board of Directors of the Canadian Chapter of the Society of Quality Assurance (CCSQA), for which he also served as Vice President in 2013, and President in 2014. David holds a Bachelor of Science in Biology from McGill University.

Paul Sidney, BS

Vice President,
GLP Quality Assurance

Paul joined Altasciences as Senior Director, Compliance and Regulatory Affairs, in 2020, with over 35 years' experience in regulatory affairs and compliance. He has held senior management roles developing and directing multi-site GLP and GCP regulatory programs. He started his career with Sandoz Pharmaceuticals in the Medical Affairs department, in a team preparing and submitting new drug submissions to Health Canada.

He subsequently joined BioResearch Laboratories (now Charles River Laboratories) initially managing a team of auditors assuring compliance for regulated nonclinical toxicology studies and clinical research in a Phase I clinical research unit. His regulatory and compliance responsibilities grew within Charles River Laboratories to provide multi-site global oversight both in GLP/GCP regulated research, as well as a quality systems and regulatory lead supporting the corporate mergers and acquisitions team.

The latter role required that quality systems and compliance programs be developed and implemented in European and North American sites. Paul has maintained an active role in many regulatory, quality and compliance societies (RAPS, SQA, RQA, ASQ, and CCSQA). He was the founding president of the CCSQA, and has presented on regulatory and compliance topics at society conferences and academic institutions in Europe, North America, Japan and China. Paul holds a Bachelor of Science from McGill University, Montréal, QC.

Natasha Savoie

Senior Director Quality,
Clinical and Research Services,
Laval, QC

Natasha Savoie joined Altasciences in 1999 as a team manager in the bioanalytical laboratory. She participated in turning the laboratory into a regulated environment from a research facility, as well as helping to obtain our OECD GLP recognition. Her extensive bioanalytical background led to a compliance role and then to the Quality Assurance department, by way of corporate training, where she helped to create Altasciences' corporate training program. In her bioanalytical and QA roles, Natasha has hosted hundreds of sponsor audits and well over 40 successful international regulatory inspections.

Natasha has been with the QA department since 2013, increasing her responsibilities to oversee QA for the Altasciences' clinical and bioanalytical facilities. Natasha actively participates in the Society of Quality Assurance, where she is the past co-chair of the Bioanalytical Specialty Section. She is also part of the teams that organizes the annual "Workshop on Recent Issues in Bioanalysis", and the annual Global CRO Council Forums, participating in the authorship of over 30 articles and white papers. Natasha is proud of Altasciences' excellent quality and inspection history, and actively works with operations in order to ensure our customers' expectations are exceeded.

Stephen Rogenthien

Senior Director Quality, CMDO
Seattle, WA

Stephen Rogenthien has over 25 years of experience in GLP and GMP compliance operations, and has been responsible for leading compliance programs and initiatives within several CROs. He has managed site-wide quality system operations and administration, including those operations that were required to be compliant with FDA and EPA Good Laboratory Practices (GLP) and quality standards of other regulatory bodies (ICH, OECD, JMAFF, MHLW, etc.).

In previous roles, he managed quality assurance programs for compliance with FDA and EPA GLP and international GLP regulatory standards, as well as developed and monitored short- and long-term site-wide compliance objectives. Stephen has maintained a leadership role in the industry, having held the role of vice president and president of the Society of Quality Assurance (SQA). He has also served as chair on specialty sections in the SQA (notably bioanalytical).

A respected professional in the industry, Stephen has demonstrated strong leadership in building effective compliance programs in nonclinical research and GMP support laboratories.

KEY PROGRAM AND PROJECT MANAGERS

- Laura McIntosh, PhD, Executive Director, Program Management and Regulatory Affairs
- Jennifer Chown, Director, Strategic Programs
- Marie Simerly, BS Director, Scientific Project Management
- Kat Connors, Director, Multisite Clinical Trial and Strategic Operations
- Jason Boehme, Associate Director, Program Management
- Lisanne Grenier, Associate Director, Scientific Project Management
- Allen Rogers, Program Director
- Danielle Dart, Senior Scientific Program Manager
- Amber Henry, Senior Scientific Project Manager
- Siomara Hernandez-Rivera, PhD, BS, Scientific Program Manager
- Cathy Ortner, MS, BS, Scientific Program Manager
- BalaKrishnaReddy Pulagam, MS, Scientific Program Manager
- Nirmala Chinnappareddy, BVSc, PhD, DABT, ERT, Scientific Program Manager
- Ariel Buhlinger, Senior Program Manager
- Oscar McClyde, MBA, BSc, Senior Project Manager II

MORE PROGRAM AND PROJECT MANAGERS on next page

KEY PROGRAM AND PROJECT MANAGERS

- Trisha O'Connell, Senior Project Manager
- Sandra Fuentes, Senior Project Manager
- Suhaills Perez-Carrillo, BS, Senior Scientific Project Manager
- Rachel Feldman, MSc, BSc, Senior Scientific Project Manager II
- Abi Chavez Rodriguez, Associate Scientific Project Manager
- Adelma Molina-Carranza, Associate Scientific Project Manager
- Aimée Quintana, MS, BS, Associate Scientific Project Manager
- Jacki Kutzler, BS, Scientific Project Manager
- Alexander Brezina, BS, Senior Scientific Project Manager II
- Alex Greathouse, MBA, BHS, Scientific Project Manager
- Amy Lamb, BA, Senior Scientific Project Manager
- Amy Lorandeau, MA, BA, Associate Scientific Project Manager
- Amy Moreno, Associate Scientific Project Manager
- Heather Winkler, BSc, Scientific Project Manager
- Chloe Stauffer, Scientific Program Manager
- Lissette Altoro, Project Manager

MORE PROGRAM AND PROJECT MANAGERS on next page

KEY PROGRAM AND PROJECT MANAGERS

- Marie-Cordia Mayoyo Kabamba, BSc, Scientific Project Manager
- Stephanie McCardle, Project Manager
- Kristina Martinu Aurousseau, PhD, Director, Strategic Clinical Operations
- Talita Conte, PhD, Scientific Project Manager
- Darshan Patel, Scientific Project Manager
- Kamie LeClair, BS, Scientific Project Manager
- Lane Zander, BSc, Senior Scientific Project Manager II
- Urbee Mahmood, Project Manager
- Ryan Chiantello, BS, Scientific Project Manager
- Oluwaseyi (Haduwa) David-Joseph, MBA, PMP, Scientific Project Manager

Laura McIntosh, PhD

Executive Director, Program Management and Regulatory Affairs

Laura McIntosh, PhD, joined Altasciences in 2022 and leads the program management and Scientific and Regulatory Affairs teams. She graduated from the University of Manitoba with a doctorate in Cell Biology, before undertaking postdoctoral studies in early diagnostic tools for skin cancer. Laura's robust scientific knowledge is combined with extensive experience in leadership and product development—having previously tenured as a venture partner and led R&D in multiple biotech startups to develop innovative biological products and services.

Laura is driven by a passion for understanding clients' long-term strategies, finding inspiration in customizing programs with a comprehensive solution. Her commitment to understanding the bigger picture and anticipating all stages of the sponsor's drug development strategy is foundational to efficiently leading each program.

Jennifer Chown

Director, Strategic Programs

Jennifer Chown joined Altasciences in 2024 as Director of Strategic Programs, bringing 24 years of experience in preclinical research and a passion for novel medications for new indications, data science enhancements, and regulatory strategies.

Prior to joining Altasciences, Jennifer worked as Associate Director of Alliance Management at Charles River Laboratories, with oversight of the global program management team. In this position, she developed experience and interest in working with customers to optimize their drug development process through strategic partnering and effective collaboration.

Jennifer has extensive experience in leadership, regulatory affairs, process improvement, and quality risk management, as well as program and alliance management. She received a Bachelor of Science in Microbiology and Immunology from McGill University, QC.

Marie Simerly, BS

Director, Scientific Project Management

Marie Simerly is a certified Project Management Professional (PMP) with over 25 years of early phase project management leadership experience, who joined Altasciences in 2025. She specializes in strategic client partnerships and program management, for which she has developed, implemented and led at multiple global CROs for over twenty years. She also has a demonstrated history of excellence in leading process improvement projects, including those utilizing Lean and Six Sigma methodology.



Kat Connors, MS, BS

Director, Multisite Clinical Trial and Strategic Operations

Kat Connors joined Altasciences in 2018 and is a clinical operations leader with more than 18 years of CRO experience across preclinical research, early-phase clinical development, project management, and trial implementation. Her background spans both operational delivery and strategic oversight, with a focus on consistent execution in highly regulated environments.

In her current role as Director of Multisite Clinical Trial & Strategic Operations, Kat leads the design and implementation of scalable approaches for complex multisite studies. She works closely with cross-functional teams and external stakeholders to support site engagement, maintain operational consistency, and translate study strategy into practical execution across early-phase and proof-of-concept programs. Her responsibilities include overseeing Project Managers and Research Services teams, supporting process improvement efforts, and contributing to risk management and quality-focused study delivery.

Kat holds a Master of Science in Project Management and a Bachelor of Science in Animal Sciences from the University of Wisconsin–Platteville. She is known for a collaborative leadership style and an emphasis on clear, proactive communication.

Jason Boehme

Associate Director, Program Management

Jason Boehme joined Altasciences in 2018 as a Program Manager with over 20 years of experience, over 17 of which has been spent in the CRO industry, including 10 years in preclinical research and over seven years in clinical research.

Working in clinical research, Jason managed a variety of studies including Phase I, II, and III, SAD/MAD, DDI, TQT, dermatology, renal and hepatic impairment, CNS, and endocrine in both healthy normal volunteers and patients.

Since joining Altasciences, Jason has gained additional experience working in a variety of studies, drawing on his vast experience to problem-solve and implement projects quickly and within budget. His experience includes internal and external site management, oversight of data services (data management, biostatistics, programming, clinical monitoring, and medical writing) and working with various preclinical and clinical vendors.

Lisanne Grenier, PhD, MSc, BSc

Associate Director,
Scientific Project Management

Lisanne Grenier is experienced associate director in scientific project management and has been with Altasciences since 2014. Her vast knowledge of cross functional departments, clinical operations, program and employee management helps her optimize processes, problem solve, and led her team to implement projects successfully.

For the past three years she has been program managing strategic client, supervising direct reports and financial subject matter expert which has given her a right tools to guide operations and to provide good customer service with quality work.

Allen Rogers

Program Director

Allen Rogers joined Altasciences in 2025 as Program Director, bringing nearly 35 years of safety assessment experience in the pharmaceutical, biopharmaceutical, medical device, veterinary medicine, agrichemical and industrial chemical industries.

With a vast wealth of experience across technical, scientific, leadership and commercial roles throughout, Allen's career has included positions at companies such as Eli Lilly and Company, Covance, Charles River Laboratories, and MPI Research.

Allen has extensive leadership, safety assessment, regulatory and program management experience, with a passion for helping customers achieve their product development goals as seamlessly and cost effectively as possible. Allen holds a Bachelor of Science in Wildlife from the University of Wisconsin–Stevens Point.

Danielle Dart

Senior Scientific Program Manager

Danielle Dart joined Altasciences' nonclinical laboratory in Columbia, Missouri, in 1999 and has over 20 years of industry experience in laboratory science and *in vivo* operations, having occupied several different positions from veterinary technician, to scientist to assistant director of research and director of compliance.

Danielle has assisted in development of several key operations including NHP services, animal model development, equipment inventory and validation, archives, document control, training, and test material processes. She directed compliance efforts as quality assurance management and key contact to regulatory inspection agencies and accrediting bodies.

Danielle assisted in the achievement of ISO 10993 accreditation for medical device services and served as IACUC Chairman for over 15 years.

Amber Henry

Senior Scientific Project Manager

Amber Henry joined Altasciences in 2025, and is a Senior Scientific Project Manager with extensive experience in large and small molecule method development, raw material testing, finished product testing and all phases of clinical research. Her experience was gained through various roles in biopharma testing facilities, central labs, and contract research organizations.

With more than eight years of industry experience, she has managed complex projects across a range of early-phase clinical studies, including but not limited to SAD/MAD, first-in-human, BA/BE, DDI, and food effect studies. Amber excels in driving cross-functional collaboration, optimizing project timelines, and ensuring alignment with regulatory standards in high-pressure environments.

Known for her strategic approach and strong communication skills, Amber has a proven ability to bridge scientific and operational teams, delivering results in the biopharma and CRO sectors.



Siomara Hernandez-Rivera, PhD, BS

Scientific Program Manager

Siomara Hernandez-Rivera joined Altasciences in 2023 and is a seasoned scientific program manager that has successfully led numerous preclinical studies between CROs and sponsors. Siomara has successfully managed studies in a wide variety of study designs and therapeutics areas from gastrointestinal diseases, CNS, oncology, enteric nervous system, behavioral, PTSD, female reproductive diseases, and HIV/AIDS.

Prior to joining Altasciences, Siomara's preclinical research experience included 13 years in which she held positions as a research lead and study director, and in study management. These experiences enable Siomara to anticipate potential risks and to execute projects on time, on budget, and with the highest quality. Siomara studied a Bachelor of Science in Biology at the University of Puerto Rico, Mayaguez, and a doctorate in Biomedical Sciences at Ponce Health Sciences University.

Cathy Ortner, MS, BS

Senior Scientific Program Manager

Cathy Ortner joined Altasciences in 2020. As Senior Program Manager, she works closely with the preclinical, clinical, CDMO, CRO services, and bioanalytical teams to ensure delivery of quality packages to support successful IND and CTA submissions. She also works to implement process improvements to better support our clients.

With 17 years of CRO experience, Cathy brings a breadth of knowledge to the Altasciences team. Prior to joining Altasciences she launched and led an archival team before moving into quality assurance and then project management. She also holds a Master of Science in Clinical Research Management from Washington University in Saint Louis, MO.

BalaKrishnaReddy Pulagam, MS Scientific Program Manager

BalaKrishnaReddy (Bala) Pulagam joined Altasciences in 2024 as a Program Manager. He has extensive experience in overseeing bioanalytical projects, animal health studies, and clinical projects. Bala earned a Master of Science in Medicinal and Pharmaceutical Chemistry from the New Jersey Institute of Technology (NJIT), and has over 10 years of preclinical and clinical experience at various contract research organizations. He has also worked as a scientist, where he developed and validated LC/MS/MS assays for pharmaceutical active pharmaceutical ingredients (APIs) in various biological matrices.

Following his time as a scientist, Bala became a project manager. He worked with various clients simultaneously and served as a single point of contact for clients on bioanalytical, animal health studies, and clinical projects.

Nirmala Chinnappareddy, BVSc, PhD, DABT, ERT

Scientific Program Manager
Seattle, WA

Nirmala Chinnappareddy joined Altasciences in 2022. She is a board-certified toxicologist with more than 15 years of experience in designing, conducting, and reporting of efficacy, mechanism of action, and preclinical toxicology studies to support early drug discovery and development. Nirmala earned her a Bachelor of Science in Veterinary Medicine, and a doctoral degree in Veterinary Pharmacology and Toxicology from Bangalore Veterinary College, India—in addition to postdoctoral trainings from Ontario Veterinary College, University of Guelph, and Atlantic Veterinary College, University of Prince Edward Island, Canada.

Nirmala's areas of expertise include cardiovascular pharmacology, CNS pharmacology, and regulatory toxicology. Prior to joining Altasciences, she worked as a research toxicologist, regulatory toxicology specialist, and research scientist supporting early drug discovery and regulatory submission of human and animal health products.

Ariel Buhlinger, BS

Senior Program Manager

Ariel Buhlinger joined Altasciences in 2015, bringing ten years of experience in the CRO industry, including three years in program management, with a focus on operations and study coordination.

During Ariel's first years working in CROs, she gained experience in management, quality control, and toxicology research working with both non-GLP and GLP studies. With this knowledge, she has found her niche in program management. Ariel understands the needs of sponsors and works to implement strategies to ensure they achieve their preclinical goals.

Oscar McClyde, MBA, BSc

Senior Project Manager II

Oscar McClyde joined Altasciences in 2024, bringing more than ten years of experience managing Phase I to IV clinical trials. Oscar is an experienced Scientific Project Manager who has worked across a diverse range of therapeutic areas, including endocrine, oncology, neurology, vaccines, ophthalmology, dermatology, and pediatrics. He has supported a variety of study designs, such as bioequivalence and bioavailability studies, SAD and MAD studies, proof of concept trials, and electronic clinical outcome assessments (eCOA).

Oscar's skills in communication, leadership, problem solving, process improvement, forecasting, risk management and are key assets driving his success in managing multiple projects simultaneously. He has a Bachelor of Science in Chemistry and a Master of Business Administration in Applied Management.

Trisha O'Connell

Senior Project Manager

Trisha O’Connell joined Altasciences in 2018 and is a seasoned Senior Scientific Project Manager who has successfully led numerous Phase I clinical trials across her 20-year career. Trisha has successfully managed studies in a wide variety of study designs and therapeutic areas, including Phase I studies such as FIH, SAD/MAD, DDI, TQT, HAP/HAL, and therapeutic areas that include renal and hepatic impairment.

Prior to joining Altasciences, Trisha’s clinical research experience includes 4 years at a clinical trial management software company as a project manager and director of customer support services, and two years as an editor developing CRFs, SAPs, and supporting statistical programming documentation.

Sandra Fuentes

Senior Scientific Project Manager

Sandra Fuentes joined Altasciences in 2024 and is an experienced and accomplished senior project manager with a proven record of leading delivery teams from project initiation through operational close out. She successfully manages multiple studies with tight deadlines and budgets while fostering productive and enduring client relationships.

From her initial role in clinical research as a clinical project coordinator, she has advanced to Senior Project Manager in just under seven years as a result of her excellent skills in communication, cross-functional coordination, team leadership and collaboration, scope management, and client relationship management.

Suhaills (Sue) Perez-Carrillo, BS

Senior Scientific Project Manager

Sue Perez-Carrillo joined Altasciences in 2024 and is a seasoned Senior Project Manager with fifteen years of clinical research experience focused primarily on early phase trials.

Her experience in various roles within clinical research has contributed to strengthening her ability to oversee full-service Phase I studies. Sue has also contributed to business development and quality assurance efforts, while effectively leading a team comprising project managers, coordinators, and clinical trial associates.

Sue is recognized for her leadership abilities and adeptness at cultivating relationships, with extensive experience in managing both client and team dynamics.



Rachel Feldman, MSc, BSc

Senior Scientific Project Manager II

Rachel Feldman is a seasoned senior scientific project manager who joined Altasciences in 2022. She has successfully led numerous Phase I clinical trials and managed studies in a variety of designs and therapeutic areas—including Phase I SAD/MAD and bioequivalence trials in the area of cardiovascular and diabetes.

Prior to joining Altasciences Rachel's clinical research experience includes 6 years as a PM managing first in human, pivotal and post market medical device studies in the cardiovascular space using multiple sites across the globe. In addition, Rachel has contributed to study design development and strategic alliances with experts in the cardiovascular field. This experience enables Rachel to anticipate potential risks and to execute projects on time, on budget, with the highest quality.

Rachel earned a Bachelor of Science in Biology at Concordia University, as well as a Master of Science in Medical Genetics at the University of Montréal.

Abi Chavez Rodriguez

Associate Scientific Project Manager

Abigail (Abi) Rodriguez joined Altasciences in 2021 as a Scientific Project Coordinator. She previously worked at Altasciences' clinical site in Los Angeles, CA, as an assistant in study operations, where she handled dosing and clinic responsibilities and served as a regulatory assistant specialist. Abigail works closely with project managers to provide support, ensuring client projects are on track and on time.

Abigail assists with maintenance of the trial master files and is involved in building and maintaining communication with internal and external stakeholders.

Adelma Molina-Carranza

Associate Scientific Project Manager

Adelma Molina-Carranza joined Altasciences after working in clinical trials for several years. She joined Altasciences as a laboratory assistant in 2013 before moving into laboratory technician and coordinator roles, before becoming an Associate Project Manager.

Adelma's experience spans Phase I studies, preclinical research, bioequivalence, single and multiple ascending dose trials, drug-drug interaction studies, as well as cardiovascular, respiratory, and 505(b)(2) research. In addition to managing the site, she handles data services such as biostatistics, programming, clinical monitoring, and medical writing.

Aimée Quintana, MS, BS

Associate Scientific Project Manager

Aimée Quintana joined Altasciences in 2022, and is a highly accomplished scientific project manager, overseeing a series of successful clinical studies, with hands-on experience across Phase I and II preclinical studies.

Her experience allows her to anticipate potential issues and manage projects effectively within established timelines and budgets, while consistently upholding the highest quality standards. She is committed to applying her expertise and dedication to excellence in all scientific projects. Aimée holds a Master of Science in Kinesiology and Physical Education, with focus in biomechanics from McGill University, Toronto, ON.

Jacki Kutzler, BS

Scientific Project Manager

Jacki Kutzler joined Altasciences in 2022, and has since successfully managed several clinical trials. She previously worked in the CDMO space for 15 years, working in various roles. Jacki graduated with a Bachelor of Science in Chemistry from Arcadia University, PA.

Alexander Brezina, BS

Senior Scientific Project Manager II

Alex Brezina joined Altasciences in 2015, and is a seasoned scientific project manager who has successfully led numerous Phase I clinical trials at Altasciences. Prior to joining project management, Alex worked for four years in the clinic in a variety of roles, including phlebotomist and study manager. Alex has successfully managed studies in a wide variety of study designs and therapeutic areas, including Phase I, study types such as SAD/MAD, DDI, TQT, and therapeutic areas like dermatology, human abuse potential, ophthalmologic, etc.

Alex's rich experience has enabled him to proactively anticipate potential risks and deliver projects of the highest quality. Alex studied Microbiology at North Dakota State University.

Alex Greathouse, MBA, BHS

Scientific Project Manager

Alex Greathouse joined Altasciences in 2025, bringing more than six years of experience in clinical research focused on early-phase trials, particularly in metabolic studies. Prior to her role at Altasciences, she worked as a project coordinator for various sponsors and indications. She has successfully managed studies across a wide range of designs and therapeutic areas, including gastroenterology, metabolic and endocrinology, oncology, pediatrics, and genetics.

Prior to joining Altasciences, Alex served as a clinical study coordinator for a pediatric genetic repository, before serving as a senior clinical trial manager on a variety of Phase II and Phase III GLP-1 studies. Alex studied Health Sciences and Business Administration at the University of Missouri–Kansas City.

Amy Lamb, BA

Senior Scientific Project Manager

Amy Lamb joined Altasciences in 2015 and has successfully led numerous Phase I clinical trials. She has managed studies across a wide range of study designs and therapeutic areas, including Phase I and II trials, tobacco research, SAD and MAD studies, DDI assessments, TQT studies, first-in-human trials, and research involving renal and hepatic impairment. Additionally, she has experience in managing external sites. Before joining Altasciences, Amy spent 15 years as a study manager (clinical research coordinator) and five years as an associate director of clinical research and studied Zoology at North Dakota State University.

Amy Lorandeau, MA, BA

Scientific Project Manager

Amy Lorandeau joined Altasciences in 2023 as an experienced scientific project manager with over 20 years of experience in leading global drug development programs, including research and development and Phase I to IV clinical trials. She has managed studies across a broad range of therapeutic areas, including oncology, hematology, neuroscience, autoimmune diseases, metabolic disorders, ophthalmology, cardiovascular health, infectious diseases, and gastroenterology.

Amy oversees studies across various phases and designs at all three clinical sites. She excels in managing cross-functional teams within a matrix environment and is proficient in resource planning, risk management, and budget oversight. Amy holds a Master of Arts in Clinical Psychology from Loyola University in Chicago, IL, and has furthered her education in research methodology and post-graduate biostatistics at the Johns Hopkins University School of Medicine in Baltimore, MD.

Amy Moreno, MS

Associate Scientific Project Manager

Amy is an Associate Project Manager in science who joined Altasciences in 2020. She has contributed to various studies, including Phase I to II clinical trials, SAD and MAD studies, as well as ethnobridging studies. Before taking on her current role, she worked as a project coordinator, supporting various project managers across all clinical sites.

Amy holds a Master of Science in Pharmaceutical Sciences from Western University of Health Sciences in Pomona, CA.

Heather Winkler, BSc

Scientific Project Manager

Heather Winkler is a project manager who joined Altasciences in 2022, bringing early clinical development and Phase I coordination experience. Heather has progressed from project coordination to associate project management in a wide variety of Phase I study designs.

Heather has experience managing studies at all three of Altasciences clinical sites. Heather studied Human Biology at the University of Wisconsin-Green Bay, WI.

Chloe Stauffer

Scientific Program Manager

Chloe Stauffer joined Altasciences in 2022 as Quality Assurance Associate before transitioning to the project manager team in 2023, and the program manager team in 2025. With over six years of professional experience in various roles within CDMOs, including analytical chemist and analytical reviewer, Chloe brings a depth of experience-based knowledge to her position.

As Program Manager, Chloe is responsible for overseeing project timelines, coordinating with various departments, and ensuring the successful delivery of client projects. Her extensive background enables her to gauge and communicate project timelines with accuracy.

Chloe has experience working with a diverse range of drug products, including topicals, liquid-filled capsules, powder-filled capsules, oral solutions, and drug-coated pellets.

Lissette Altoro, MBA, BSc

Project Manager

Lissette Altoro joined Altasciences in 2019, and is an experienced scientific project manager with experience in leading numerous Phase I clinical trials. Her expertise encompasses a wide variety of study designs and therapeutic areas, including but not limited to bioequivalence, bioavailability, Phase I and II studies, and drug-drug interaction studies. Lissette has worked in various therapeutic areas such as human abuse liability, ethno-bridging, tobacco, renal impairment, CNS, cardiovascular, and gastroenterology.

Lissette's keen attention to detail has been essential in managing studies aimed at developing partnership alliances. With over 20 years of clinical experience in emergency medicine, nuclear cardiology, psychiatry, and trauma surgery in teaching hospitals, ambulatory services, and outpatient settings, Lissette is adept at anticipating potential risks and executing projects on time, within budget, and with the highest quality standards. She studied biology and healthcare administration at South University, KS.

Marie-Cordia Mayoyo Kabamba, BSc

Scientific Project Manager

Marie-Cordia Mayoyo Kabamba joined Altasciences in 2013 and is an accomplished scientific project manager who has successfully led numerous clinical trials in her years at Altasciences. She started as a laboratory analyst and worked her way up to the scientific project management team.

Marie-Cordia has managed studies in a wide range of study designs and therapeutic areas such as bioequivalence, bioavailability, Phase I study types like 505b2, DDI, SAD/MAD, and therapeutic areas like human abuse liability/potential, ethno-bridging, hepatic and renal impairment, cardiovascular and gastroenterology.

Marie-Cordia studied biochemistry at the Université de Montréal, QC, and business administration at HEC Montréal.

Stephanie McCardle

Project Manager

Stephanie McCardle joined Altasciences in 2023 as a scientific project manager, and has over 13 years of clinical research experience, primarily working in early-phase trials. Stephanie has collaborated with many internal and external site management teams and various clinical vendors, and her vast experience has enabled her to problem-solve and implement projects quickly and efficiently.

Stephanie excels at managing a cross-functional team in a matrix environment, and she regularly and proactively manages risk while adhering to escalation procedures. Stephanie thrives on providing great customer service while establishing excellent long-term partnerships with sponsors.

Kristina Martinu Aurousseau, PhD

Director, Strategic Clinical Operations

Kristina Martinu Aurousseau joined Altasciences in 2020. She obtained her doctorate in Biomedical Sciences at Montréal University, studying Parkinson's disease and the effects of Levodopa on patients' brain activity through fMRI. After working as a laboratory coordinator in the pain field, she eventually joined the contract research organization industry in 2017 as Study Director in an infusion and neurotox department, where she ran a number of studies of varying dose routes such as subcutaneous, intrathecal infusion and injection, and intra-cerebrovascular administration.

Since 2018, she has been part of the nonclinical project management team, helping sponsors to stay on track for their deliverables and submission deadlines.

Talita Conte, PhD

Scientific Project Manager

Talita Conte joined Altasciences as a Project Manager in 2022. Talita has a doctorate in genetics, and prior to joining Altasciences, had worked for more than ten years with preclinical and clinical research and therapeutic testing.

She has acquired a vast experience in early-phase trials (Phase I to IIb, single or multi-site) in various domains. Her background encompasses both internal and external site management, as well as the supervision of data services such as data management, biostatistics, programming, clinical monitoring, and medical writing. Talita showcases outstanding organizational skills, which she leverages to craft comprehensive study timelines and oversee projects seamlessly, from their initial award to the ultimate delivery of results.



Darshan Patel, PhD

Scientific Project Manager

Darshan Patel is a Scientific Project Manager at Altasciences, where he has been working since 2017. He has successfully managed and overseen a wide range of clinical study designs and therapeutic areas, including studies involving drugs and devices, as well as Phase I, II, and III trials with exceptional expertise.

Experienced in various types of studies, including Japanese bridging studies, FIH, DDI, SAD, MAD, food effect studies, and bioavailability and bioequivalence studies, Darshan possesses a comprehensive understanding of numerous therapeutic areas, and is adept at managing multiple studies running simultaneously—facilitating seamless collaboration across all three clinical sites.

Kamie LeClair, BS

Scientific Project Manager

Kamie LeClair joined Altasciences in 2022, bringing a wealth of experience in research and project management. Working closely with clients and internal teams, she oversees studies across the full spectrum of nonclinical and clinical development programs, including CDMO, investigational device, and Phase I and II studies.

Kamie has extensive experience with multiple Phase I study types, including SAD, hepatic impairment, food effect, and bioequivalence, and has managed studies at all three Altasciences clinical.

Prior to joining Altasciences, Kamie gained substantial research experience, including three years as a project coordinator, three years as Assistant Director of an academic IRB office, and four years as a project specialist and subject matter expert (SME) at a CDMO. Kamie earned a Bachelor of Science in Biology from the University of Wisconsin.

Lane Zander, BSc

Senior Scientific Project Manager II

Lane Zander came to Altasciences in 2021 and has over 10 years' experience leading drug development programs through R&D, GLP, and Phase I and II clinical trial manufacturing.

She managed studies in a wide range of therapeutic areas and has successfully managed studies with a wide variety of Phase I designs. Lane is skilled in managing multiple, simultaneously running studies, and excels at managing a cross-functional team in a matrix environment. Lane studied Biochemistry at Kutztown University, PA.

Urbee Mahmood, MSc

Project Manager

Urbee Mahmood is a scientific project manager who joined Altasciences in 2022. Her experience includes site management, and oversight of clinical and data services including medical writing, data management, regulatory, pharmacology, programming, biostatistics and bioanalytical.

Urbee completed her Master of Science in Applied Clinical Pharmacology at the University of Toronto, ON. Her experience and proactive approach enables her to anticipate potential risks and implement projects on time, on budget, with the highest quality.

Ryan Chiantello, BS

Scientific Project Manager

Ryan Chiantello is a skilled scientific project manager who came to Altasciences in 2024 with over seven years of experience in managing Phase I to III clinical trials. He has managed studies in a wide range of therapeutic areas, including cardiology, ophthalmology, gastroenterology, neurology, immunology, dermatology, oncology, and rare diseases.

Oluwaseyi (Haduwa) David-Joseph, MBA, PMP

Scientific Project Manager

Haduwa David-Joseph joined Altasciences with more than eight years of experience leading and managing clinical research projects. She works closely with investigators, study coordinators, and sponsors to ensure all aspects of clinical trials are performed with precision and in accordance with good clinical practice (GCP) guidelines.

Haduwa's expertise includes the development and implementation of project plans, oversight of study protocols, and management of study sites and vendors. Known for her collaborative approach and strong organizational skills, Haduwa excels at fostering effective communication among cross-functional teams and maintaining productive relationships with key stakeholders. Haduwa is a certified PMP professional with a Master of Business Administration from Plymouth Marjon University, UK, and is based out of Tomball, Texas.

ALTASCIENCES

altasciences.com

PRECLINICAL FACILITY

6605 Merrill Creek Parkway
Everett, WA 98203
U.S.A.

425 407-0121

PRECLINICAL FACILITY

130 Discovery Drive
Scott Township, PA 18447
U.S.A.

800 300-8114

PRECLINICAL FACILITY

562 State Road DD
Auxvasse, MO 65231
U.S.A.

573 387-4400

PRECLINICAL FACILITY

Sacramento, CA
U.S.A.

800 300-8114

CLINICAL FACILITY

10103 Metcalf Avenue
Overland Park, KS 66212
U.S.A.

913 696-1601

CLINICAL FACILITY

5630 Cerritos Avenue
Cypress, CA 90630
U.S.A.

714 252-0700

CLINICAL FACILITY

1200 Beaumont Avenue
Montréal, QC H3P 3P1
Canada

514 381-2546

BIOANALYSIS AND RESEARCH SERVICES

575 Armand-Frappier
Boulevard
Laval, QC H7V 4B3
Canada

450 973-6077

MANUFACTURING AND ANALYTICAL SERVICES

1510 Delp Drive
Harleysville, PA 19438
U.S.A.

215 256-5920